⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Cellular Senescence
Current understanding
Zombie cells and the SASP — the mechanism behind the senolytics bet.
Evidence log
- 2026-11-12 — Aging Remodels the Female Skeletal Muscle Proteome Toward Matrix, Chromatin and Lysosomal Programs that Track Loss of Physical Function: [human-observational] Observational proteomic profiling of vastus lateralis biopsies from younger and older women identifies a 24-protein senescence-associated signature highlighting HMGB1/2 and matrix, chromatin, and lysosomal/SASP programs that correlates with lower grip strength and slower gait, without establishing senescent-cell burden, longitudinal functional decline, or benefit from senolytic treatment. [human-observational] (novelty: 3)
- 2026-11-13 — Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.: [animal-model] Endometrial stromal cell experiments and an aged-mouse study report that metformin attenuates stromal senescence alongside improved uterine histology and litter size, with functional involvement of TERT and AKT/mTOR signaling, without establishing senescent-cell clearance, durable senescence reversal, or human reproductive benefit. [animal-model] (novelty: 3)
- 2026-11-13 — Cellular senescence and the hallmarks of ageing: Evaluating evidence for a causal mechanistic role.: [expert-opinion] Review, no new primary data: classifies bidirectional causal relationships between senescence and other aging hallmarks, positioning senescence as both initiator and amplifier through cell-autonomous and non-cell-autonomous pathways rather than solely a downstream response, while leaving its causal primacy and the human benefits of targeting this proposed hub unresolved. [expert-opinion] (novelty: 3)
- 2026-11-12 — The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells: [mechanism-plausible] News report, with experimental models and primary data unspecified in the supplied summary, describes DNA-damage-response-driven PD-L1 upregulation as a route to senescent-cell immune escape, extending the checkpoint-ligand framework beyond previously logged PD-L2 findings without establishing human senolytic efficacy or safety of checkpoint blockade. [mechanism-plausible] (novelty: 3)
- 2026-11-13 — Interfering in the USP25-SIRT1 Interaction Reduces the Onset of Cellular Senescence: [mechanism-plausible] News report, with experimental models and primary data unspecified in the supplied summary, describes disruption of the USP25–SIRT1 interaction as a senostatic route to slowing senescence entry rather than killing established senescent cells, with endogenous immune clearance proposed to lower net burden but no human efficacy or safety established. [mechanism-plausible] (novelty: 3)
- 2026-11-12 — Transcriptomic Characterization of Cellular Senescence in Human Donor Livers Before Transplantation: [human-observational] Observational transcriptomic profiling of human donor livers before transplantation characterizes senescence-associated gene-expression signatures as candidate indicators of organ aging and graft quality, without establishing direct senescent-cell burden, validated prediction of transplant outcomes, or benefit from senolytic treatment. [human-observational] (novelty: 3)
- 2026-10-20 — Proteostasis stress alters mitochondrial levels and localization of SOD2 during cellular senescence.: [mechanism-plausible] Preclinical cellular senescence study reports that proteostasis disruption impairs mitochondrial localization of SOD2 and promotes its aggregation, contributing to mitochondrial oxidative stress and stress-induced premature senescence without establishing this pathway’s contribution to natural organismal aging or human therapeutic benefit. [mechanism-plausible] (novelty: 3)
- 2026-11-01 — The AIM2 inflammasome drives age-dependent cardiac dysfunction following ischemia-reperfusion in mice.: Mouse ischemia-reperfusion study [animal-model] reports AIM2-driven inflammatory cardiac injury independent of the classic senescence markers assessed, distinguishing inflammasome-associated pyroptosis from senescence-linked injury without excluding all senescent-cell contributions or establishing benefit from senolytics in this setting. [animal-model] (novelty: 3)
- 2026-11-11 — MLL, TERRA, and telomere chromatin dynamics in replicative senescence and aging.: [expert-opinion] Review, no new primary data: proposes MLL-dependent TERRA regulation and telomeric chromatin remodeling as a route linking telomere shortening to replicative senescence, without establishing this route as a universal senescence mechanism or demonstrating human therapeutic efficacy. [expert-opinion] (novelty: 3)
- 2026-11-11 — A genetically encoded system to purify senescent cells.: [mechanism-plausible] Cell-culture methods study introduces SenLect, a genetically encoded miR-146a-promoter-driven puromycin-selection system for purifying senescent cells from mixed cultures for proteomic, metabolic, and secretomic profiling, addressing proliferating-cell contamination without establishing coverage of all senescent subtypes, organismal aging effects, or human therapeutic benefit. [mechanism-plausible] (novelty: 3)
- 2026-11-10 — The neuro-inflammaging triangle: a self-amplifying circuit of protein pathology, senescence-associated secretory phenotype and innate immunity in neurodegenerative disease.: [expert-opinion] Review, no new primary data: places cellular senescence/SASP as both a consequence and amplifier of protein pathology and innate immune activation in a proposed neurodegenerative feedback circuit, without demonstrating that senolysis or combined targeting interrupts this circuit or improves human clinical outcomes. [expert-opinion] (novelty: 3)
- 2026-11-01 — Inflammaging as a Dynamic Process in Ageing: Context, Regulation and Functional Consequences.: [expert-opinion] Review, no new primary data: incorporates senescent-cell heterogeneity and immune escape into a four-state inflammaging model, proposing that their context-dependent contributions shape inflammatory persistence without demonstrating reversal of cellular senescence or human benefit from stage-specific senotherapy. [expert-opinion] (novelty: 3)
- 2026-11-10 — A Supplement Kills Senescent Cells and Extends Life in Mice: [animal-model] News coverage of a Nature Aging mouse study reports that late-life vanadyl sulfate supplementation selectively cleared senescent cells and extended healthspan and median lifespan in male mice, adding a candidate senolytic without establishing that clearance mediated the survival benefit or that supplementation is effective and safe for human aging. [animal-model] (novelty: 4)
- 2026-11-09 — Senescence‐Associated Loss of α‐Synuclein in Brain Microvascular Endothelium Compromises Tight Junctions and Disrupts Blood–Brain Barrier Integrity: [mechanism-plausible] Preclinical mechanistic study reports that senescence-associated loss of α-synuclein in brain microvascular endothelium compromises tight junctions and blood–brain barrier integrity, identifying a loss-of-function route to senescence-related tissue dysfunction without establishing its contribution to human brain aging or benefit from senotherapy. [mechanism-plausible] (novelty: 3)
- 2026-11-09 — TMAO regulates renal tubular epithelial cell senescence through circVmn2r1.: [animal-model] Mouse and cultured renal tubular epithelial cell experiments report that TMAO promotes tubular senescence and kidney-aging phenotypes through circVmn2r1 upregulation and NLRP3 inflammasome activation, identifying a metabolite-triggered renal senescence pathway without establishing its relevance or therapeutic tractability in humans. [animal-model] (novelty: 3)
- 2026-11-03 — Senescent CD8 T effector memory cells are functionally impaired, enriched in aging and disease, and a barrier to immunotherapy.: Preclinical functional experiments with human senescent CD8 effector-memory T cells report impaired elimination of senescent stromal cells and inhibition of checkpoint-blockade responses [mechanism-plausible], extending the existing clearance-failure framework beyond macrophages and target-cell checkpoint ligands without demonstrating that restoring T-cell fitness reduces senescent-cell burden in patients. [mechanism-plausible] (novelty: 3)
- 2026-11-09 — The lncRNA SEPT5-GP1BB-encoded peptide ARP, upregulated by 17β-estradiol, retards HO-induced senescence of human umbilical vein endothelial cells by promoting autophagy.: [mechanism-plausible] Cultured human umbilical vein endothelial cell experiments report attenuation of stress-induced senescence through a 17β-estradiol–ARP–autophagy pathway, without establishing clearance of existing senescent cells, durable senescence reversal, or human therapeutic efficacy. [mechanism-plausible] (novelty: 3)
- 2026-11-09 — Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.: Review synthesis [expert-opinion], with no new primary data, extends the existing CAR-T senolysis framework by highlighting senescent-cell antigen heterogeneity and immunosuppressive aged microenvironments as barriers to translating reported preclinical clearance and healthspan benefits into selective, safe human therapy, without establishing human efficacy or superiority over other senolytics. [expert-opinion] (novelty: 3)
- 2026-11-09 — CASM regulates lysosomal expansion and cell fate during senescence.: Preclinical mechanistic study [mechanism-plausible] reports that CASM-dependent TFEB activation drives senescence-associated lysosomal expansion and that CASM inhibition redirects stressed cells toward apoptosis rather than senescence, without establishing selective clearance of established senescent cells, organismal aging benefits, or human efficacy and safety. [mechanism-plausible] (novelty: 3)
- 2026-11-03 — Evidence for spermine oxidase (SMOX) as a regulator of skeletal muscle mass throughout the lifespan.: Review synthesis [expert-opinion], with no new primary data reported, links SMOX-mediated spermidine generation to reduced skeletal-muscle senescence markers and preserved muscle function, without establishing senescent-cell clearance, durable senescence reversal, or human sarcopenia prevention. [expert-opinion] (novelty: 3)
- 2026-03-31 — Reprogramming the mitochondrial-circadian energy code with incretins.: Review proposal [expert-opinion], with no new primary data reported, places senolytics alongside incretin agonists, NAD+ support, and circadian entrainment in a multimodal geroprotection strategy, without demonstrating combination synergy, senescent-cell clearance by incretins, or human anti-aging efficacy and safety. [expert-opinion] (novelty: 3)
- 2026-08-07 — MDM2 deletion and its associated p53 activation in subcutaneous white adipose tissue induce hepatic fibrosis via galectin-3 in a mouse model.: [animal-model] Mouse genetic study reports that selective MDM2 deletion in subcutaneous white adipose tissue sustains p53 activation, induces adipocyte senescence, and promotes remote hepatic fibrosis via increased adipocyte-derived galectin-3 secretion, identifying an adipose-to-liver pathway without establishing its contribution to natural aging or human disease. [animal-model] (novelty: 3)
- 2026-10-23 — Leptin Neutralization Attenuates Inflammaging in Endothelial and Immune Cell Models.: [mechanism-plausible] Cell-culture experiments identify leptin as an mTOR-linked promoter of senescence and SASP in endothelial and immune models, with receptor blockade attenuating these readouts without establishing senolytic clearance, durable reversal of senescence, or human efficacy. [mechanism-plausible] (novelty: 3)
- 2026-11-02 — Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.: Cell and aged-mouse study [animal-model] reports that DGLA depletion permits damaged cells to persist in senescence, while exogenous DGLA selectively induces ferroptotic senescent-cell clearance and oral supplementation improves functional outcomes in aged mice, identifying a lipid-metabolic senolytic route without establishing human efficacy or safety. [animal-model] (novelty: 4)
- 2026-11-05 — Resistant hypertension and accelerated vascular aging: evidence for PTEN-AKT-associated cellular senescence.: Human observational study with in vitro follow-up associates resistant hypertension with endothelial cellular senescence [human-observational] and implicates reduced PTEN–AKT restraint as a candidate senescence mechanism [mechanism-plausible], without demonstrating that senescence causes treatment resistance or that senotherapy improves human blood-pressure outcomes. [human-observational] (novelty: 3)
- 2026-10-28 — Identification of an Endothelial Senotype Predicted by Ion Channel Expression in Aged Murine Perigonadal Adipose Tissue.: Aged-mouse perigonadal adipose single-nucleus RNA-sequencing study [animal-model] identifies a senescence-associated capillary endothelial subpopulation with elevated Mif expression and predictive ion-channel transport gene profiles, extending cell-type-specific senotype mapping without establishing causal roles for these genes, functional senescence validation, or human applicability. [animal-model] (novelty: 3)
- 2026-05-21 — A photo-responsive, fisetin-functionalized DNA nanocage for programmed therapy to accelerate early-stage wound healing in aged skin.: Aged-mouse wound study [animal-model]: a photo-responsive tetrahedral DNA nanocage co-delivering fisetin and a miR-29-targeting antisense oligonucleotide reportedly cleared senescent cells and accelerated early-stage wound healing through temporally programmed release, extending localized senotherapy without establishing the independent contribution of senolysis or efficacy and safety in humans. [animal-model] (novelty: 3)
- 2026-10-23 — Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.: Preclinical colorectal cancer cell study [mechanism-plausible]: beta-ionone activation of ectopic olfactory receptor OR51E2 induced a senescence-like phenotype and increased susceptibility to dasatinib plus quercetin, extending the tumor senescence-induction–then-clearance strategy without establishing durable senescence, human cancer efficacy, or benefit against age-related senescent-cell accumulation. [mechanism-plausible] (novelty: 3)
- 2026-11-01 — Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.: Tree shrew preclinical study [animal-model] reports closer concordance with human transcriptional aging trajectories and age-related pathologies than mice, alongside human-concordant responses to dasatinib+quercetin, extending non-rodent senolytic modeling without establishing predictive validity for human clinical benefit. [animal-model] (novelty: 4)
- 2026-10-09 — Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.: 2026 ovarian immunoregulation review implicates granulosa, theca, and stromal cell senescence plus SASP as part of the ovarian immune-microenvironment remodeling driving reproductive decline and POI, framing ovarian senolytics/senomorphics alongside immunomodulation — synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-10-08 — Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.: 2026 MASLD Perspective proposes a stage-specific senotherapy framework sequencing short-term senolytic clearance with longer-term senomorphic/metabolic maintenance, stratified by disease stage and selection/timing/response biomarkers — translational framing on top of existing senescence biology (and the D+Q MASH RCT already logged), no new empirical readout. [expert-opinion] (novelty: 3)
- 2026-10-08 — Phosphodiesterase 4 inhibitors extend lifespan of C. elegans and attenuate cellular senescence of mouse embryonic fibroblasts.: PDE4 inhibitors roflumilast/rolipram preclinical study: roflumilast attenuated passage-induced senescence in mouse embryonic fibroblasts via PKA-mediated mitochondrial improvements and reduced oxidative stress — adds approved PDE4 inhibitors (cAMP/PKA axis) to the senomorphic roster acting upstream through mitochondrial rescue, no in vivo mammalian or human senescence readout. [animal-model] (novelty: 3)
- 2026-10-10 — THE AGING PURINOME: A PURINERGIC FRAMEWORK LINKING THE HALLMARKS OF AGING TO INFLAMMAGING.: 2026 Aging Purinome review implicates purinergic receptor signaling and NAD±related metabolism in SASP amplification and senescent-cell communication within a proposed systems framework linking the hallmarks to inflammaging — synthesis only, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-23 — Galangin attenuates UVB-induced skin photoaging through SIRT1-dependent LC3 deacetylation and autophagy modulation.: 2026 UVB-induced skin photoaging study: galangin reduces dermal fibroblast senescence, MMPs, and collagen loss in HDFs and mouse skin via a SIRT1→LC3-deacetylation→autophagy axis, extending the natural-product senomorphic roster for photoaging and tying skin senescence rescue to a specific sirtuin-autophagy post-translational node. [animal-model] (novelty: 3)
- 2026-09-30 — An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer: Open-label pilot trial (no placebo, no randomization) in adult survivors of childhood cancer testing short-course dasatinib+quercetin and fisetin monotherapy with blood p16INK4a senescent-cell burden and frailty measures (gait speed) as endpoints — extends D+Q and fisetin senolytic testing to a treatment-induced accelerated-aging survivor population, protocol-stage with no efficacy readout yet. [human-rct] (novelty: 3)
- 2026-10-01 — Precision Microbiota Interventions for Senoreduction Trial: Early randomized crossover trial of GRAS microbiota-targeted interventions in people with HIV who drink alcohol uses immune-senescence biomarkers as endpoints, framing the microbiome as an upstream lever on senescence biology in a high-burden population — protocol only, no readout, and senescence biomarkers are immune-cell-level rather than tissue senescent-cell burden. [human-rct] (novelty: 3)
- 2026-10-06 — Declining Autophagy Impairs Senescent Cell Clearance: News-report framing of a preclinical study tying age-related autophagy decline to failed immune clearance of senescent cells, with pathway activation reducing senescent-cell signs in aged mice — reinforces (does not add new primary data to) the CMA→macrophage-clearance axis already logged. [animal-model] (novelty: 3)
- 2026-09-29 — uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor: Preclinical mouse + non-human primate study: a uPAR-targeting GFD-CD3 bispecific T-cell engager cleared uPAR+ senescent cells and alleviated age-related pathologies at low doses, with serum aminotransferase (ALT/AST) activity working as a titratable on-treatment safety biomarker — extends uPAR-directed senolysis (previously uPAR-nanoparticle D+Q, uPAR CAR-T) into an off-the-shelf T-cell-redirecting modality with first NHP data and a defined clinical safety readout, no human efficacy yet. [animal-model] (novelty: 4)
- 2026-09-30 — Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization: Preclinical scleroderma study: parthenolide binding of Ero1L stabilized mitochondria-associated ER membranes and reduced cellular senescence alongside dermal fibrosis in localized scleroderma models, adding a MAM-stabilization route (upstream of senescence) and nominating an Ero1L-targeting natural product to the senomorphic roster — no human readout. [animal-model] (novelty: 3)
- 2026-10-06 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan: Phenotypic drug-discovery screen nominates novel flavonoid senotherapeutics that reduced cellular senescence and improved multiple healthspan markers in preclinical models, extending the flavonoid senolytic/senomorphic roster (alongside quercetin, fisetin) with new chemical matter from an unbiased screen rather than a targeted mechanism — no human readout. [animal-model] (novelty: 3)
- 2026-10-01 — Dietary CoQ10 Ameliorates Age-Related Megakaryocyte Dysfunction via COPS3-Mediated Activation of Autophagy.: Aged-mouse study touches senescence biology only tangentially: dietary CoQ10 ameliorated age-related megakaryocyte dysfunction and platelet hyperreactivity via COPS3-mediated autophagy restoration, with no direct SA-β-gal/p16/SASP readouts — extends the roster of upstream autophagy-restoring dietary levers proposed to counter age-related lineage dysfunction rather than a direct senolytic/senomorphic finding. [mechanism-plausible] (novelty: 3)
- 2026-07-28 — Enhancing the anti-ageing capacity of hUC-MSCs via NMN co-treatment in D-galactose-induced ageing mice and cellular senescence models.: D-galactose aging-mouse + cellular senescence model: co-administration of human umbilical cord MSCs with NMN outperformed either monotherapy, with NMN protecting transplanted hUC-MSCs from senescence via Nrf2/HO-1 activation — adds an NAD-precursor-plus-MSC combination to the stem-cell/anti-oxidant senomorphic roster and nominates donor-cell Nrf2/HO-1 reinforcement as an upstream lever against transplanted-MSC senescence, preclinical only. [animal-model] (novelty: 3)
- 2026-10-01 — Ghrelin Alleviates Aging-Related Cognitive Impairment by Regulating Autophagy-Related Signaling via the SHBG/JNK1/Beclin1 Axis in Microglia.: Mouse + cell preclinical study with human association data: ghrelin attenuates microglial senescence through SHBG/JNK1/Beclin1-mediated autophagy induction, adding microglia-in-cognitive-aging to the tissue-specific senescence roster with autophagy restoration as the upstream lever. [animal-model] (novelty: 3)
- 2026-04-30 — Long-term cerebrovascular effects of cyclophosphamide and vincristine: endothelial senescence, impaired DNA repair signaling, and blood-brain barrier dysfunction.: 2026 mouse study: clinically relevant cyclophosphamide (but not vincristine) drove persistent cerebrovascular endothelial senescence with upregulated DNA-damage checkpoints and downregulated DNA-repair genes, adding brain endothelium under a specific alkylator chemotherapy to the agent-resolved, tissue-specific senescence roster (chemo-induced skin JAK-STAT senescence, doxorubicin cardiac senescence, gemcitabine PDAC stromal senescence) and sharpening agent-specificity within ‘chemo-induced senescence’. [animal-model] (novelty: 3)
- 2026-10-01 — Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.: 2026 review positions endothelial TLR4 as an upstream, cell-type-specific trigger of the endothelial senescence program and proposes TLR4-directed senotherapeutics via precision carriers (nanoparticles, plant exosomes) as a candidate addition to the targeted-delivery senotherapy roster — synthesis only, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-10-05 — Electroacupuncture Targeting the NLRP3 Inflammasome in Senescence‑associated Cognitive Impairment: Mechanistic Synthesis and Meta‑analysis of Clinical Randomized Controlled Trials.: 2026 electroacupuncture meta-analysis (9 RCTs, n≈599, MCI/early AD) touches senescence biology only via the NLRP3/SASP-adjacent IL-6 reduction framing; no direct senescent-cell burden or SASP-panel readouts, so the link to senescence biology is inferential rather than measured. [mechanism-plausible] (novelty: 3)
- 2026-10-06 — Multimodal Technology-Driven aging Research: Decoding the Mitochondria‒Pyroptosis axis in muscle atrophy and cognitive decline.: 2026 multimodal-technology review touches senescence biology only tangentially, framing pyroptotic tissue hotspots in aging muscle and brain as a cell-death-mode alternative/companion to the SASP-driven senescent-cell narrative rather than measuring senescent-cell burden directly — synthesis only. [expert-opinion] (novelty: 3)
- 2026-10-05 — Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.: Preclinical cell + aged-mouse study: age-related loss of chaperone-mediated autophagy allows senescent-cell persistence by rewiring SASP and blocking macrophage efferocytosis of senescent targets; pharmacologic CMA activation reduces senescent-cell burden in aged mice and in a pulmonary fibrosis model, extending the roster of upstream proteostasis levers on senescent-cell clearance beyond immune-checkpoint (PD-L2) and direct senolytic chemistries. [animal-model] (novelty: 4)
- 2026-10-05 — Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.: 2026 PRISMA systematic review of completed human clinical trials of senolytics (notably dasatinib+quercetin) and senomorphics finds preliminary biological and functional signals but insufficient evidence to establish clinical efficacy or long-term safety — synthesis-level consolidation of the small human-trial corpus, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-05 — Senotherapeutic potential against xeroderma pigmentosum.: Preclinical drug screen in XP patient-derived iPSC-melanocytes: BCL-2-like and HSP90 senolytics plus JAK-inhibitor and curcuminoid senomorphics cleared or suppressed UV-induced senescent cells and SASP, extending established senolytic/senomorphic classes into a xeroderma pigmentosum photoaging context and adding XP melanocytes to the tissue-specific senescence roster — in vitro only, no in vivo or human readout. [mechanism-plausible] (novelty: 3)
- 2026-10-06 — Resveratrol protects primary hepatocytes against senescence induced by endogenous toxic metabolites.: In vitro primary hepatocyte study (human and porcine): 5 µM resveratrol reversed a newly defined ‘SILT’ (senescence induced by endogenous liver toxins) phenotype and partially restored albumin and urea synthesis in a species- and function-dependent manner, with transcriptomic concordance to diseased-liver datasets — adds a toxin-driven hepatocyte senescence subtype to the tissue-specific senescence roster and extends resveratrol’s senomorphic action into primary liver epithelial cells. [mechanism-plausible] (novelty: 3)
- 2026-03-11 — Communication breakdown: senescent cells in interorgan communication of aging.: 2026 opinion review frames senescent cells as central hubs of interorgan aging communication, with SASP factors and immune-driven inflammaging propagating senescence signals systemically — reinforces the circulating-senosome / EV / altered-intercellular-communication thread already logged, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-01 — Inflammaging reshapes the immune ecosystem in IgG4-related dacryoadenitis and sialadenitis.: 2026 IgG4-RD lesional transcriptome: aged-patient lesions show coordinated SASP/senescence signatures alongside stromal and fibrotic activation, adding lacrimal and salivary gland lesion tissue to the tissue-specific senescence roster in a human autoimmune fibrotic disease — descriptive observational only, no senescent-cell burden quantification. [human-observational] (novelty: 3)
- 2026-09-28 — Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.: Preclinical macrophage study: pharmacologic NLRP3 inhibition with MCC950 increased senescent cell burden rather than reducing it, nominating NLRP3-mediated apoptosis as a tonic clearance mechanism whose blockade pushes aged macrophages toward senescence instead. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.: Aged atherosclerotic mouse scRNA-seq study: rapamycin lowered senescent leukocyte transcriptional signatures within plaque and lymphoid tissues alongside immune reprogramming, nominating leukocyte senescence as one arm of plaque-local senescent burden tractable by systemic mTOR inhibition — no direct SASP cytokine panel. [animal-model] (novelty: 3)
- 2026-07-25 — SIRT3 inhibition promotes age-associated vascular impairment by mediating mitochondrial dysfunction and endothelial-to-mesenchymal transition.: 2026 preclinical study links SIRT3 loss in senescent HUVECs and aged/Sirt3-KO mouse vasculature to mitochondrial dysfunction and EndMT, adding a mitochondrial-sirtuin node whose decline accompanies endothelial senescence and a mesenchymal-fate drift — no direct SASP readout reported. [animal-model] (novelty: 3)
- 2026-04-08 — Extracellular matrix-associated molecules of senescent cells induce a senescence phenotype in proliferative cells via TGF-β signaling pathway.: 2026 preclinical study: decellularized ECM from senescent vascular cells and fibroblasts induces a senescence phenotype in proliferative endothelial cells via TGF-β signaling, both in culture and after implantation into young mice — extends the paracrine-senescence roster beyond soluble SASP and EVs to the matrisome/ECM itself as a transmissible senescence-inducing substrate. [animal-model] (novelty: 3)
- 2026-05-22 — circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone.: 2026 aged-mouse preclinical study: systemic apoptosis-mimicking LNPs delivering circRNA reprogram macrophages into anti-MMP9 antibody biofactories, reducing stem-cell senescence and SASP in bone and cartilage and rejuvenating aged skeletal tissue — adds a cell-free gene-delivery route that turns host macrophages into localized SASP-dampening antibody factories, extending the targeted-biologic senotherapy roster (alongside uPAR T-cell engagers, PD-L2 blockade, and nanoparticle-delivered senolytics) with no human readout. [animal-model] (novelty: 4)
- 2026-05-25 — A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.: 2026 preclinical bone-defect study (senescent BMSCs + aged mouse bone defects): a dual NAD supplementation-plus-biosynthesis nanoplatform (N/S@M@P) with sustained local release reduced the senescent BMSC fraction while restoring NAD/NADH and ATP and improving aged bone regeneration — adds a locally delivered NAD-restoration modality to the senomorphic roster acting on BMSC senescence via bioenergetic rescue, no human data. [animal-model] (novelty: 3)
- 2026-06-16 — Resveratrol suppresses GATA4/Sortilin pathway to attenuate vascular smooth muscle cell senescence-associated secretory phenotype and vascular aging-related atherosclerosis.: 2026 ApoE mouse + VSMC study: resveratrol attenuated VSMC senescence and SASP by suppressing a GATA4/Sortilin pathway, extending the GATA4-upstream-of-SASP axis (previously logged for radiation-induced atrial senescence) into vascular smooth muscle and nominating Sortilin as a downstream effector; adds another natural-compound senomorphic candidate acting on this axis. [animal-model] (novelty: 3)
- 2026-06-27 — IL-11 neutralizing antibodies alleviate pulmonary fibrosis in aging mice by inhibiting TGF-β/NOX4/IL-11 signaling pathway.: 2026 aged-mouse pulmonary fibrosis study: IL-11 neutralizing antibodies reversed the profibrotic phenotype of senescent lung fibroblasts and attenuated early and late pulmonary fibrosis via inhibition of a TGF-β/NOX4/IL-11 signaling loop — adds IL-11 to the roster of SASP-adjacent cytokines whose neutralization reverts senescent-fibroblast-driven tissue fibrosis in aged lung. [animal-model] (novelty: 3)
- 2026-07-08 — The autophagy-senescence-inflammasome axis: A novel triad in neurodegenerative diseases?: 2026 neurodegeneration review positions glial senescence as one node of an Autophagy–Senescence–Inflammasome (ASI) feed-forward triad in which SASP primes inflammasome activation while inflammasome output reinforces senescence entry — reframing of existing glial-senescence biology, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-11 — Cellular viscous properties in senescence: An emerging biophysical perspective and potential biomarker.: 2026 biophysics review argues cellular viscous properties — not just elastic stiffness — change with senescence and could serve as a biophysical biomarker for senescent-cell detection and senolytic response readouts, extending the mechanical/physical-senotype arm of senescence biology toward rheological measurements; synthesis of methods and prior cell-mechanics data, no new primary senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-12 — Targeting the JAK-STAT signaling pathway ameliorates chemotherapy-induced skin aging.: 2026 preclinical mouse + HDF study: chemotherapy-induced DNA damage activates JAK-STAT signaling to drive dermal fibroblast senescence and SASP, and ruxolitinib (JAK1/2 inhibitor) ameliorates chemo-induced skin aging phenotypes while also suppressing tumor progression — extends the JAK-STAT senomorphic arm to a chemotherapy-induced skin senescence context and nominates dual skin-protective/antitumor framing for an approved JAK inhibitor. [animal-model] (novelty: 3)
- 2026-07-14 — A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.: 2026 human-focused compendium review of circulating senescence biomarkers consolidates GDF15 and Activin A as the most cross-study-replicated SASP factors indexing systemic senescence burden across neurodegenerative, pulmonary, cardiometabolic, and musculoskeletal domains, and catalogs modulation by emerging drug and lifestyle senotherapeutics — synthesis of prior human observational biomarker literature, no new primary senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-14 — Mechanical signals in aging: mechanisms and therapeutic strategies.: 2026 review on mechanical signals in aging frames cellular mechanics and mechanotransduction as critical regulators of senescence initiation and progression and nominates mechanics-based interventions (mechanical stimulation, microenvironment stiffness remodeling, targeted mechanotransduction modulation) as candidate senotherapies — synthesis extending the physical/mechanical arm of senescence biology, no new primary senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-01 — Senescent cardiac cells promote thrombus formation and impair fibrinolysis.: 2026 in vitro study on doxorubicin-induced senescent human cardiac fibroblasts and endothelial cells: senescent cardiac cells promoted thrombin generation and fibrin polymerization while impairing fibrinolysis, with the senostatic rapamycin attenuating the pro-thrombotic phenotype — extends the cardiac-senescence SASP roster to a hemostasis/coagulation output distinct from fibrotic/paracrine-hypertrophy readouts, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-08-02 — Brain aging clocks: From methodological advances to cellular mechanisms.: 2026 brain aging clocks review nominates cellular senescence (neurons, astrocytes, microglia, cerebrovascular endothelium) as a mechanism implicated by cellular-resolution brain clocks in accelerated neural aging, extending the tissue-specific senescence roster to brain-clock-derived readouts; synthesis only, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-10-01 — The Intersection of Immunosenescence, Cellular Senescence, and Type 1 Diabetes: Paving the Way for Future Interventions.: 2026 T1D review nominates β-cell cellular senescence and SASP as both consequence and amplifier of islet autoimmunity, framing senolytics/senomorphics as candidate T1D prevention/treatment levers — extends the tissue-specific senescence roster to pancreatic β-cells in an autoimmune (not just metabolic T2D) indication, synthesis only with no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-28 — Stress-Induced Senescence of Human Umbilical Cord Mesenchymal Stromal Cells Caused by Mitomycin C.: In vitro human umbilical cord MSC study: mitomycin C induced DNA double-strand breaks and p53/p21/p27-driven proliferation arrest without hallmark senescence features (no SA-β-gal/SASP phenotype), framing perinatal MSCs as resistant to classical senescence entry despite DDR activation — refines the DDR-arrest-versus-senescence distinction and extends the roster of cell types where DDR engagement uncouples from a full senescent program. [mechanism-plausible] (novelty: 3)
- 2026-09-29 — Autologous cytokine-induced NK cells as candidate cellular senolytics: evidence, obstacles, and the experiments still needed.: 2026 synthesis review reframes mature autologous cytokine-induced NK cell platforms as candidate cellular senolytics and specifies precursor experiments (autologous NK cytotoxicity against senescent targets, preclinical infusion studies) that should gate any first-in-human program — extends the cell-therapy senolytic roster (alongside CAR-T, uPAR-targeting T-cell engagers) with a lymphocyte-infusion modality while flagging the biology-to-pitch gap, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-29 — Low-power infrared laser on telomere maintenance in an experimental model of arthritis.: 2026 mouse arthritis PBM study is positioned as senescence-prevention adjacent via upregulation of shelterin genes (TRF2/POT1/TIN2) under high-fluence infrared laser, but reports no direct senescence markers (p16/p21/SASP) — a mechanistic-plausibility link from a photobiomodulation modality to the telomere-capping arm of senescence biology. [animal-model] (novelty: 3)
- 2026-10-01 — Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.: 2026 preclinical IPF study (in vitro fibroblasts + bleomycin mouse model): systems prioritization of senescence-associated fibrotic signatures nominated syringin as a modulator of the ATR/CHK1–p53 DNA-damage-response axis that attenuated fibroblast senescence and bleomycin-induced pulmonary fibrosis — adds a natural-product senomorphic candidate acting upstream through the ATR/CHK1 DDR arm (distinct from direct p16/p21 or Bcl-2-family senolytics) to the IPF/lung-fibroblast tissue-specific senescence roster, no human data. [animal-model] (novelty: 3)
- 2026-05-23 — Chronic low-grade hippocampal inflammation blunts exercise-induced neurogenesis and alters the exercise-induced microglia transcriptome in the rat hippocampus.: 2026 adult-rat hippocampal IL-1β study: chronic low-grade inflammation drove microglial lipid-droplet accumulation (a lipid-droplet-accumulating microglia phenotype associated with aged/senescent-like microglia) that worsened despite exercise, nominating sustained cytokine exposure as an upstream input to a senescence-adjacent microglial state — no direct SASP or p16/p21 readout. [animal-model] (novelty: 3)
- 2026-07-19 — The circulating senosome: Blood as the therapeutic interface of aging.: 2026 ‘circulating senosome’ review positions SASP factors and senescent-cell-derived EVs as one layer within an integrated blood-borne mediator network, embedding senescence biology into a systemic blood-interface framing rather than tissue-local SASP; synthesis, no new senescence measurements. [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.: 2026 CSDH geroscience minireview maps chronic subdural hematoma onto cellular senescence/SASP as one of twelve hallmarks and nominates senolytics as candidate CSDH gerotherapeutics — synthesis-level target proposal with no preclinical or clinical senolytic data in CSDH yet. [expert-opinion] (novelty: 3)
- 2026-10-01 — Hepatocyte Growth Hormone Receptor Ablation Is Associated With Aging Phenotypes and Hepatic Mitochondrial Dysfunction.: Mouse hepatocyte-specific GHR knockout study: tissue-autonomous loss of liver GH signaling produced systemic aging phenotypes alongside hepatic mitochondrial dysfunction and steatosis via a PPARγ–PDK4/CD36 axis — touches senescence biology only indirectly via the aging-phenotype readout, no direct SASP or senescence-marker measurement reported. [animal-model] (novelty: 3)
- 2026-09-29 — Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.: 2026 long-term human skin explant platform (up to 4 weeks, preserved architecture): senolytic-associated treatment reduced SASP factor output in aged skin tissue ex vivo — adds a human-tissue preclinical readout for SASP modulation that sits between cell culture and in vivo human testing, no clinical outcome. [mechanism-plausible] (novelty: 3)
- 2026-09-30 — Lifelong Epstein-Barr virus persistence as a stress test of ageing immune surveillance: from infectious mononucleosis to chronic active EBV disease and virus-associated malignancy.: cross-connection with ebv-latency-immune-surveillance-aging: EBV reactivation and EBV-driven lymphoproliferation are framed as consequences of failed surveillance that overlaps with the failed-clearance narrative applied to senescent cells, suggesting shared age-related effector deficits. (novelty: 3)
- 2026-08-18 — Multivariable-adjusted multi-omics signatures reveal gut microbial functional alterations and metabolic dysregulation in intrinsic capacity decline.: 2026 observational multi-omics study in older adults flags ‘senescence-related metabolites’ as part of the serum metabolite signature associated with intrinsic capacity decline (adjusted for age, sex, comorbidity, diet) — peripheral metabolite-level trace of senescence biology in a human functional-aging cohort, no direct senescent-cell burden measurement. [human-observational] (novelty: 3)
- 2026-07-04 — Effects of nutritional interventions on biomarkers of cellular senescence in humans: A systematic review.: 2026 systematic review of 27 human nutritional-intervention trials finds effects concentrated on SASP/inflammatory biomarker profiles rather than on classical senescent-cell abundance markers (p16/p21), with caloric restriction the most consistent SASP modulator — human-trial-level evidence that current nutritional levers in people shift the secretory phenotype more than the senescent-cell burden readouts the senolytics narrative is built on. [human-rct] (novelty: 3)
- 2026-07-13 — PFDA exposure promotes myocardial aging and fibrosis via hyperactivation of the MTORC1 signaling axis.: 2026 preclinical cell + mouse study: the PFAS compound PFDA (perfluorodecanoic acid) drove cardiomyocyte senescence alongside myocardial fibrosis via mitochondrial dysfunction, inflammation, and MTORC1 hyperactivation — adds a specific persistent organic pollutant (PFAS) to the roster of environmental triggers of tissue-specific (cardiomyocyte) senescence, alongside PM2.5, lead, manganese, and cigarette smoke. [animal-model] (novelty: 3)
- 2026-04-02 — Ceramic-based biomaterials: Combining regeneration with anti-senescence.: 2026 preclinical bone-regeneration study: hardystonite (ZnCS) silicate bioceramic releasing Zn²⁺ and silicate ions delayed BMSC senescence and accelerated osteoporotic bone regeneration via a PI3K–AKT–SIRT1 axis, reportedly outperforming dasatinib+quercetin in head-to-head preclinical comparison — nominates ion-releasing bioceramics as an ‘intrinsically senotherapeutic’ (SAS) scaffold class, no human data. [animal-model] (novelty: 4)
- 2026-06-22 — Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.: 2026 aged-mouse burn-wound study: dasatinib+quercetin cleared senescent cells at post-burn wound sites and improved macroscopic healing, myofibroblast markers, and type I collagen deposition versus untreated aged burns — extends D+Q senolytic rescue into an aged acute-injury (burn wound) context and adds burn-wound stromal/epithelial cells to the tissue-specific senescence roster. [animal-model] (novelty: 3)
- 2026-10-01 — Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.: 2026 phase-2 proof-of-principle RCT in fibrotic MASH (paired-biopsy primary endpoint): intermittent dasatinib+quercetin produced ≥1-stage fibrosis improvement without MASH worsening in 47% vs 7% on placebo and higher MASH-resolution rates, with snRNA-seq showing reduced senescent and fibrogenic cell populations — first human RCT biopsy-level efficacy readout for D+Q senolytics, extending a long preclinical D+Q roster into a liver-disease indication but still a single small early-phase trial. [human-rct] (novelty: 4)
- 2026-01-25 — Targeted delivery of senolytic drugs using macrophage membrane-camouflaged magnetic nanoparticles inhibits endplate sclerosis.: 2026 LSI-mouse preclinical study: macrophage-membrane-camouflaged magnetic nanoparticles loaded with ABT-263 achieve dual-targeted (magnetic + biomimetic homing) senolytic clearance of senescent-like macrophages in degenerating vertebral endplates, extending targeted ABT-263 delivery platforms (alongside uPAR-, neutrophil-membrane-, and L1CAM-DNAzyme-based carriers) to the endplate/IVDD context. [animal-model] (novelty: 3)
- 2026-05-26 — A taxifolin-zinc nanozyme with SOD-like activity attenuates oxidative-stress-induced senescence and extends lifespan in C. elegans.: 2026 preclinical nanozyme study: a taxifolin–zinc coordination nanozyme with SOD-like activity suppressed oxidative-stress-induced senescence markers in cells and extended C. elegans lifespan/healthspan — adds a polyphenol-metal coordination nanozyme to the senomorphic/antioxidant roster targeting the ROS→senescence arm, no mammalian in vivo data. [animal-model] (novelty: 3)
- 2026-06-04 — Targeting NFAT5 attenuates high sodium-induced vascular aging by re-sensitizing senescent smooth muscle cells to apoptosis.: 2026 preclinical cell + mouse study: high sodium drives NFAT5-dependent Bcl-XL transcription in vascular smooth muscle cells, rendering senescent VSMCs apoptosis-resistant; the NFAT5 inhibitor KRN5 restored apoptosis sensitivity and acted as a senolytic — nominates an osmo-/sodium-responsive transcription factor as an upstream switch for senescent-cell apoptosis resistance distinct from Bcl-2-family-direct senolytics (ABT-263/navitoclax), still animal/cell only. [animal-model] (novelty: 3)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: 2026 preclinical package in aged mice and non-human primates: a uPAR-targeting GFD-CD3 bispecific T-cell engager cleared uPAR+ senescent cells and alleviated age-related pathologies when dosed low with serum aminotransferase monitoring as a titration/safety biomarker — nominates a dose-titratable off-the-shelf T-cell engager alternative to senolytic CAR-T, extending uPAR-directed senolysis (previously nanoparticle-delivered D+Q) into immune-redirection therapeutics with first NHP data. [animal-model] (novelty: 4) [animal-model] (novelty: 4)
- 2026-01-26 — High-protein diet promotes aging by activating the CG6415/AMT gene and disrupting mitochondrial homeostasis.: cross-connection with mitochondrial-dysfunction: CG6415/AMT-driven mitochondrial disruption engages p53–p21, placing dietary-protein-triggered mitochondrial failure upstream of a canonical senescence effector arm. (novelty: 3)
- 2026-05-28 — Feedback loops between DNMT1 and autophagy as well as senescence promotes organ aging and canities.: Mouse study: age-elevated DNMT1 protein hypermethylates senescence-gene promoters while senescence reciprocally stabilizes DNMT1, forming a DNMT1↔senescence feedback loop; senolytics and DNMT1 inhibition both broke the loop and attenuated organ-aging and canities phenotypes — adds a methyltransferase-protein node to the roster of upstream regulators of the senescence program. [animal-model] (novelty: 3)
- 2026-10-01 — A Deep-Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes.: 2026 study derives a deep-learning blood proteomics SASP Score from large-scale human plasma proteomics that independently predicts all-cause mortality and incident chronic diseases, and shows the score is significantly reduced by an 18-month multimodal exercise intervention in an external RCT cohort — operationalizes systemic senescence burden as a measurable, modifiable human biomarker rather than a tissue-level construct. [human-observational] (novelty: 4)
- 2026-10-01 — Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.: 2026 TCM-and-aging review maps multi-herb TCM formulas onto the senescence/SASP arm of the hallmarks, framing network-pharmacology dissection and proteomic aging clocks as the translational bridge; synthesis of preclinical formula data, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-10-02 — lncRNA H19 downregulation mediates oxidative stress-induced osteogenic dysfunction.: 2026 preclinical osteoblast study: ROS-driven lncRNA H19 downregulation impairs osteogenic differentiation (differentiation failure, not direct senescence readout) — touches the senescence page only via the shared oxidative-stress upstream axis implicated in bone-cell SASP, no SASP or p16/p21 measurements. [mechanism-plausible] (novelty: 3)
- 2026-09-23 — Parishin B, a phenolic constituent of Gastrodia elata Blume, extends lifespan and improves stress resistance in Caenorhabditis elegans.: Parishin B (Gastrodia elata phenolic) attenuated cellular senescence in mammalian cells alongside ~24% C. elegans lifespan extension and reduced Aβ toxicity — extends the natural-product senomorphic roster with cell-culture-level senescence-marker readouts, no in vivo mammalian data. [mechanism-plausible] (novelty: 3)
- 2026-09-12 — Soluble pathogenic tau transmission to astrocytes drives acute oxidative damage, cellular senescence, and neurovascular uncoupling in a model of Alzheimers tauopathy: 2026 tauopathy-model preclinical study: soluble pathogenic tau taken up by astrocytes drives p16/SASP senescence programs downstream of mitochondrial ROS, adding astrocytes-in-tauopathy to the tissue-specific senescence roster and nominating tau oligomer uptake as an upstream trigger of glial senescence. [animal-model] (novelty: 3)
- 2026-09-25 — Fisetin to Improve Vascular Function in Older Adults: 2026 pilot RCT protocol testing intermittent fisetin in older adults with circulating SASP factors and senescent-cell burden as mechanistic secondary endpoints alongside vascular function — extends fisetin senolytic testing beyond D+Q protocols into a vascular-aging population, no efficacy readout yet. [human-rct] (novelty: 3)
- 2026-09-15 — An Entirely New Target for Fighting Senescence: News-report coverage nominates the poorly characterized protein PTCHD4 as a newly identified senescence-linked target, adding another candidate node to the roster of upstream/marker proteins proposed for senotherapy — no primary data reviewed here, and no in vivo or human readout. [mechanism-plausible] (novelty: 3)
- 2026-09-23 — Extracellular Vesicles From Senescent Cancer Cells Are Necessary and Sufficient to Drive Paracrine Senescence: Preclinical loss-and-gain study: extracellular vesicles from senescent cancer cells are both necessary (EV depletion blocks transmission) and sufficient (isolated EVs alone reproduce it) to induce paracrine senescence in recipient cells, refining the EV arm of SASP-independent senescence propagation. [mechanism-plausible] (novelty: 3)
- 2026-09-19 — 3D-Printed and Biofabricated Scaffolds for Osteoporotic Bone Defect Repair: Mechanical Adaptation, Redox Control, Senescence Modulation and Osteoimmunomodulation.: 2026 scaffold-design review for osteoporotic bone defects positions cellular senescence as one leg of a self-reinforcing triad (oxidative stress ↔ senescence ↔ type-H vessel loss) that scaffolds should address via a sequential senescence-modulation axis, extending senotherapy discussion to biomaterial platforms — nearly all senescence-targeting scaffold evidence remains preclinical. [expert-opinion] (novelty: 3)
- 2026-09-21 — Orchestrating Stress Granule Dynamics by SUMOylation: A New Frontier in Treating Stress-Induced Age-Related Diseases.: 2026 SUMO–stress-granule review touches senescence only tangentially, framing failed SG disassembly as a proteostatic-stress input feeding into age-related decline that overlaps SASP-adjacent chronic-stress states — no direct senescence readouts. [mechanism-plausible] (novelty: 3)
- 2026-09-15 — Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.: 2026 aged-mouse study: the hepatokine hepassocin (HPS) declines with age and restrains hepatocyte senescence and enables liver regeneration by activating AMPK via an ANXA2–ERK–p90RSK–LKB1 cascade; exogenous HPS or AICAR rescues aged mice, adding a circulating liver-secreted factor to the roster of upstream anti-senescence signals in hepatic tissue. [animal-model] (novelty: 3)
- 2026-09-16 — Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesis.: Human observational CH study links DNMT3A-mutant clones to a cell-intrinsic senescence-inflammatory signature via retrotransposable-element derepression, adding hematopoietic DNMT3A loss to the roster of upstream triggers wiring chromatin decompaction to a SASP-like program. [human-observational] (novelty: 3)
- 2026-09-16 — Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.: 2026 mouse study: endothelial C/EBPβ/AEP-driven NAMPT cleavage and NAD depletion trigger endothelial senescence as a proximal step to vascular deterioration and shortened lifespan, adding a proteolytic-NAD-collapse route to the roster of upstream endothelial senescence triggers; AEP inhibition or NMN reverses senescence phenotypes in Tie2-C/EBPβ mice. [animal-model] (novelty: 4)
- 2026-09-20 — Aging-associated loss of CPEB4 impairs mitochondrial adaptation and promotes stress-induced senescence in alveolar type II cells.: 2026 mouse alveolar type II cell study: aging-associated loss of CPEB4 impairs mitochondrial adaptation via reduced TP53INP2, sensitizing AT2 cells to stress-induced (not basal) senescence — adds a post-transcriptional RNA-binding-protein node upstream of AT2 senescence and refines the stress-inducible vs baseline senescence distinction in lung epithelium. [animal-model] (novelty: 3)
- 2026-09-22 — Modeling pancreatic islet aging: mitochondrial dysfunction and functional rescue in 3D organoids by exogenous mitochondrial delivery.: Senescent pancreatic islet 3D organoid model links β-cell senescence to loss of glucose-sensing machinery (glucokinase/GSIS) via mitochondrial failure; exogenous mitochondrial delivery partially restored insulin secretion, adding pancreatic islets to the tissue-specific senescence roster and nominating mitochondrial transfer as a functional-rescue modality distinct from senolysis/senomorphics — organoid-only, no in vivo readout. [mechanism-plausible] (novelty: 3)
- 2026-09-14 — Clearance of p16-positive cardiac cells improves age-related cardiac remodeling in mice.: 2026 mouse genetic-clearance study: midlife-to-old-age ablation of p16-positive cells attenuated age-related left-ventricular hypertrophy and wall thickening and normalized diastolic dysfunction, implicating senescent cardiac fibroblasts and cardiomyocytes with a fibroblast paracrine hypertrophy signal — extends p16+ senolysis into cardiac remodeling and HFpEF-adjacent physiology. [animal-model] (novelty: 3)
- 2026-09-15 — LSD1-mediated demethylation of the DNA damage response factor ATM promotes senescence and organ aging.: Preclinical study: LSD1-mediated demethylation of ATM at K3016 sustains DDR signaling to drive senescence in multiple aged tissues; pharmacologic LSD1 inhibition lowered senescence markers and blocked irradiation-induced hair graying — adds a lysine-demethylase node upstream of DDR-driven SASP. [animal-model] (novelty: 4)
- 2026-09-16 — Quantitative proteomics reveals coordinated changes in the proteome during replicative senescence.: 2026 quantitative mass-spec proteomics of replicative senescence resolves a temporally coordinated proteome signature — chromatin and translation-machinery depletion, mitochondrial protein insolubility, and compromised autophagy/proteasome capacity — recasting the senescent state as a distinctive proteostasis-shaped remodeling rather than a set of independent marker changes; cell-culture only, no in vivo or human readout. [mechanism-plausible] (novelty: 3)
- 2026-09-17 — Stress and cancer from an integrative psychoneuroimmunology perspective: Neurobiological mechanisms and clinical implications.: 2026 psychoneuroimmunology review nominates chronic catecholamine and cortisol exposure — from HPA-axis and sympathetic activation under sustained psychosocial stress — as an under-emphasized upstream trigger of cellular senescence and SASP in cancer patients, extending the roster of stress-hormone inputs into the senescence program; narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-20 — Panvascular aging: The pioneer organ hypothesis, research models and future directions.: 2026 panvascular-aging review positions the vasculature as a systemic sender of senescence via SASP factors and extracellular vesicles from aged endothelium and VSMCs (aortic arch highlighted as earliest), extending the tissue-of-origin conversation for senescence propagation — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-21 — RamanOmics decodes the spatial vibrational-molecular architecture of senescence in aging and repair.: 2026 preclinical RamanOmics study in mouse lung and skin couples label-free hyperspectral Raman imaging with snRNA-seq/spatial transcriptomics to define tissue-specific senescence programs and a conserved lipid-linked Raman signature of p21+ senescent cells, offering a nondestructive in situ identification modality distinct from marker antibodies/scRNA-seq. [animal-model] (novelty: 4)
- 2026-09-23 — Engineered Extracellular Vesicle Revitalizing Macrophage Energy Metabolism for Aged Wound Repair.: 2026 aged/diabetic wound mouse study: 4-Octyl itaconate–engineered extracellular vesicles reversed macrophage senescence in aged skin wounds by restoring ASS1-dependent arginine–OXPHOS metabolism, adding wound macrophages to the tissue-specific senescence roster and nominating engineered-EV cargo delivery of an immunometabolite as a senomorphic modality. [animal-model] (novelty: 3)
- 2026-09-24 — The mechanisms and mechanics of aging.: 2026 mechanics-of-aging review positions cellular senescence and SASP as both a consequence and amplifier of mechanotransduction failure along the ECM–integrin–cytoskeleton–nucleus axis, tying senescent-cell accumulation to stiffened matrices and YAP/TAZ–MRTF dysregulation — conceptual integration, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-25 — Type 2 Angiotensin II receptor (AT2R) deficiency exacerbates cardiac senescence and fibrosis in aging mice.: 2026 aged-mouse AT2R knockout study: loss of the Type 2 angiotensin II receptor amplifies cardiac p53/p21 senescence and SASP with early DNA damage and worsened cardiac function, adding AT2R deficiency to the roster of upstream endocrine/receptor-level triggers of tissue-specific (cardiac) senescence. [animal-model] (novelty: 3)
- 2026-09-15 — Reprogramming the Aging Type H Vascular Niche via Myeloid Angiogenic Cell-Derived Extracellular Vesicles: Mechanisms, Engineering Strategies, and Translational Perspectives.: 2026 review argues aging remodels endothelial and myeloid EV cargo into a senescence-associated secretory phenotype that helps uncouple Type H vessels from osteogenesis, and proposes donor preconditioning and cargo engineering to overcome these senescence-associated EV liabilities in age-related osteoporosis — synthesis only, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-21 — Senescent Cell Heterogeneity: Tissue-Dependent Signatures and Age Dynamics Revealed by Human scRNA-Seq Data.: 2026 multi-tissue human scRNA-seq map (skin, lung, intestine, kidney, heart) resolves senescent-cell transcriptional signatures as strongly tissue- and cell-type-dependent, cataloging SASP programs, antigen-presentation programs, and ligand-receptor interactions with the local microenvironment — pushes the field from a monolithic ‘senescent cell’ construct toward organ- and lineage-resolved subtypes, descriptive human observational data with no clinical or interventional readout. [human-observational] (novelty: 3)
- 2026-09-15 — The Oral Microbiome-Inflammaging Axis in Elderly Periodontitis: Emerging Immunopathogenic and Systemic Mechanisms.: 2026 elderly-periodontitis review adds periodontal/gingival tissue senescence to the tissue-specific SASP roster, framing local senescent-cell burden as a component of a self-reinforcing oral dysbiosis–inflammaging ecosystem — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-20 — CSenescence-associated-secretory phenotype proteins and inflammatory pathways are involved in psychosis: A transdiagnostic study using the Human Connectome Project for early psychosis (HCP-EP) data.: 2026 HCP-Early Psychosis transdiagnostic proteomic study: early-psychosis patients showed an elevated SASP protein index versus controls, with the index correlating with higher BMI and lower psychological well-being — extends the SASP-index concept to a psychiatric population as a peripheral premature-aging readout, cross-sectional and no interventional data. [human-observational] (novelty: 3)
- 2026-09-16 — Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience.: 2026 self-correction framework review places senescence within a distributed ‘terminate and recover’ failure mode — persistent senescent cells as manifestations of impaired resolution rather than a primary aging axis; conceptual framing, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-26 — Plasma and cerebrospinal fluid proteomics reveal distinct patterns of senescence and neuropathology in aging rhesus macaques.: 2026 rhesus macaque plasma+CSF proteomics across the lifespan maps compartment-specific senescence signatures — including human-like neurosenescence markers and geriatric CSF subclusters — extending the senescence biomarker roster into a non-human primate model for translational benchmarking, no interventional readout. [animal-model] (novelty: 3)
- 2026-09-26 — The Eukaryotic Host-Microbe-Phage-Nutrition Interplay Determines the Bacterial Effectors of Supplemental Lysine’s Health Benefits: An Experimental Cellular Senescence Model of Digestive Conditions in Older Adults.: 2026 preclinical five-way cellular senescence model of older-adult digestive conditions: whether supplemental lysine helps or harms senescent gut epithelium depends on host–microbe–phage–nutrition interactions (pathogen vs beneficial anaerobe cross-feeding), positioning senescent gut epithelium as a context-dependent readout for amino-acid supplementation rather than a fixed target. [mechanism-plausible] (novelty: 3)
- 2026-05-15 — Jintiange ameliorates age-related sarcopenia by inhibiting the cGAS-STING signaling pathway via maintaining mitochondrial homeostasis.: 2026 aged-mouse Jintiange study touches senescence biology tangentially — the compound’s benefit on sarcopenia is pinned to mtDNA–cGAS–STING/NF-κB inhibition rather than direct SASP/senolytic readouts, extending the DNA-sensing arm of senescence-adjacent muscle inflammation to a TCM-compound intervention. [animal-model] (novelty: 3)
- 2026-09-18 — Ferroptosis and Ferro-Aging in Obesity: Bibliometric Mapping, Shared Mechanisms, and Translational Perspectives.: 2026 obesity–ferroptosis review nominates iron-dependent lipid peroxidation (ACSL4↑, GPX4↓) as an upstream input to a ‘ferro-aging’ senescence-like state in obese adipose and metabolic tissues, adding a lipid-peroxidation route to the roster of proposed senescence triggers — bibliometric/conceptual only, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-06-01 — Adipose tissue as a systemic modulator of brain aging: mechanistic links between metabolism, inflammation and neurodegeneration.: 2026 adipose–brain review adds senescent visceral adipocytes and their SASP/EV output to the roster of peripheral senescent-cell reservoirs proposed to accelerate brain aging, reinforcing the depot-specific (visceral vs subcutaneous/thermogenic) senescence-burden framing — conceptual synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-15 — Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy.: 2026 mouse study: ionizing radiation drives atrial remodeling and AF susceptibility via DNA-damage-induced cellular senescence through a GATA4–NF-κB–SASP axis, with dasatinib+quercetin senolytic therapy reversing atrial remodeling — extends D+Q rescue into a radiation-induced cardio-oncology (atrial fibrillation) context and nominates GATA4 as an upstream senescence-SASP node in atrial tissue. [animal-model] (novelty: 3)
- 2026-09-16 — Cellular senescence of fibro-adipogenic progenitors by STAT5A/GFPT2/O-GlcNAcylation impairs muscle recovery after glucocorticoid-induced injury.: 2026 preclinical study: glucocorticoids drive senescence of muscle fibro-adipogenic progenitors (FAPs) via a STAT5A→GFPT2→O-GlcNAcylation axis, and these senescent FAPs suppress myotube formation and muscle stem cell proliferation to impair post-injury recovery — adds FAPs to the tissue-specific senescence roster and nominates hexosamine/O-GlcNAc metabolism as an upstream node connecting iatrogenic steroid exposure to muscle regenerative failure. [animal-model] (novelty: 3)
- 2026-09-18 — Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.: 2026 TDP-43 ALS mouse study: cellular senescence markers appear early in motor cortex and spinal cord, and longitudinal dasatinib+quercetin senolysis improved motor behavior, neuromuscular function, reduced plasma NfL, and preserved layer V neurons — extends D+Q senolytic rescue into a motor-neuron-disease (ALS) model and adds ALS to the tissue-specific senescence roster. [animal-model] (novelty: 3)
- 2026-09-09 — SIRT3-dependent mitochondrial redox homeostasis protects against age-related tendon degeneration.: 2026 murine tenocyte study: SIRT3 restoration reverses oxidative senescence in aged supraspinatus tenocytes via SOD2 and Keap1/Nrf2/HO-1 pathways, adding tendon tissue to the tissue-specific senescence roster and nominating mitochondrial SIRT3 as an upstream anti-senescence lever. [animal-model] (novelty: 3) [animal-model] (novelty: 3)
- 2026-09-10 — Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.: 2026 ApoE mouse + cardiomyocyte study: mitochondria-targeted esculetin reduces cardiac cellular senescence markers alongside hypertrophy and fibrosis via AMPK–SIRT1 activation and p38 MAPK suppression, positioning a mitochondria-targeted coumarin as a senomorphic candidate in the aging heart — preclinical, no human data. [animal-model] (novelty: 3)
- 2026-06-23 — Hydrogel-based senomorphic approaches to modulate cellular senescence and promote tissue rejuvenation.: 2026 materials-science review frames hydrogels as dual-function senomorphic platforms — combining material-intrinsic bioactivity with localized, sustained release of senomorphic cargos to attenuate SASP while preserving resident cells in low-regenerative tissues; extends the targeted-delivery roster (nanoparticles, biomimetic carriers, DNAzyme platforms) toward scaffold-based senotherapy, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-13 — Nanoparticles as an efficient strategy to eliminate senescent brain endothelial cells.: 2026 aged-rat study: SA-β-gal-responsive polymeric nanoparticles loaded with Navitoclax selectively cleared p16/p21-positive brain endothelial cells at lower doses than free drug, extending targeted-delivery senolysis (alongside uPAR-nanoparticles, neutrophil-membrane biomimetics, L1CAM-DNAzyme platforms) to the cerebrovascular endothelium. [animal-model] (novelty: 3)
- 2026-08-28 — Senescent cells maintain viability through adhesion-dependent fragmentation that promotes debris deposition.: 2026 preclinical study proposes senescent cells maintain viability by shedding adhesion-dependent fragments (SCAFs) carrying damaged mitochondria and debris, which rupture to deposit DAMPs, amyloid-like material, and neurodegeneration-linked proteins — nominates a physical fragmentation route as a distinct arm of the senescence secretome alongside classical SASP. [mechanism-plausible] (novelty: 4)
- 2026-09-09 — Apolipoprotein(a)-rich electronegative HDL accelerates vascular aging and atherosclerosis by inducing endothelial senescence.: 2026 human observational + in vitro/in vivo study: Apo(a)-rich electronegative HDL subfraction H5 induces endothelial cell senescence via the p53–p21 axis, adding a circulating lipoprotein-quality trigger to the roster of upstream senescence inducers in the endothelium. [human-observational] (novelty: 3)
- 2026-09-10 — Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.: 2026 preclinical mouse study: PD-L2 is upregulated on senescent cells and shields them from immune clearance; genetic PD-L2 knockout or anti-PD-L2 antibody reduced senescent-cell burden and restored insulin sensitivity and grip strength in aged mice — nominates an immune-checkpoint axis as a senolytic-adjacent lever distinct from D+Q/ABT-263/PCC1 chemistry, no human data. [animal-model] (novelty: 4)
- 2026-09-11 — Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.: 2026 musculoskeletal-mitochondria review nominates mitochondrial dysfunction as an upstream trigger of chondrocyte, osteocyte, and synoviocyte senescence in OP/OA/RA, and positions senolytics alongside mitochondria-targeted agents in a precision-therapy matrix — synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-11 — Replicative and Air Pollution-Induced Senescence: Telomere Dysfunction, Mitochondrial Stress, and Modulatory Effects of Astragaloside IV in Endothelial and Vascular Smooth Muscle Cells.: 2026 in vitro study in human endothelial and vascular smooth muscle cells: PM2.5 (fine particulate matter) drove premature senescence via telomere dysfunction and mitochondrial impairment, with Astragaloside IV (TCM saponin) partially attenuating the endothelial senescence phenotype but showing limited benefit in VSMCs — extends the environmental-pollutant trigger list for senescence and adds cell-type-specific resistance to a natural-compound senomorphic, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-07-15 — Cinnamon polysaccharides reshape gut microbiota and enrich Alloprevotella rava to promote acetate-dependent choline metabolism and delay mammary aging.: 2026 mouse study: cinnamon polysaccharide–driven enrichment of Alloprevotella rava delayed mammary tissue senescence via an acetate→choline-metabolism→mitochondrial-function axis, nominating a dietary-polysaccharide/gut-microbe input upstream of tissue-specific senescence — mouse only, no human data. [animal-model] (novelty: 3)
- 2026-08-24 — Qinghuang powder ameliorates cellular senescence and energy metabolism abnormalities in bone marrow mesenchymal stem cells of myelodysplastic syndromes.: 2026 in vitro study on patient-derived MDS bone marrow mesenchymal stem cells: Qinghuang powder core components (arsenic sulfide AsS and indirubin) reduced senescence markers and SASP in MDS-BMMSCs, linked to AMPK activation and EZH2 modulation — extends the senescence-modulator roster to a TCM formulation in a stromal-cell/hematologic-malignancy niche context, no in vivo or human outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-17 — Cellular Senescence and COVID-19 Long-Hauler Syndrome: 2026 translational commentary/rationale extending the senolytics thesis to COVID-19 Long-Hauler Syndrome — proposes senescent-cell burden and SASP as a mechanistic substrate of post-acute sequelae and uses that rationale to argue for initiating a clinical trial of senolytics; no efficacy data, trial not yet reported. [expert-opinion] (novelty: 3)
- 2026-08-18 — A Novel Approach Utilizing Organ Specific Age Proteomics: 2026 methods/observational proposal in early-stage breast cancer: pre/post-adjuvant-chemotherapy p16INK4A T-cell expression paired with organ-specific plasma proteomic age signatures is nominated as a risk-stratification readout for chemo-related cardiac, neurologic, and functional late toxicities — operationalizes p16 as a clinical biomarker of therapy-induced senescence burden, no outcome data yet. [human-observational] (novelty: 3)
- 2026-09-10 — Inhibition of the PGAM1-CHK1 Interaction as a Novel Approach to Destroy Senescent Cells: News-report coverage of a preclinical finding that disrupting the PGAM1–CHK1 protein interaction sabotages the elevated glycolysis of senescent cells to selectively kill them — nominates a glycolytic-vulnerability senolytic angle distinct from D+Q/ABT-263/PCC1, no human data. [mechanism-plausible] (novelty: 3)
- 2026-09-10 — NAD+ Metabolic Reprogramming Drives CD8+ T Cells Senescence and Exacerbates Ulcerative Colitis: Already logged 2026-09-01 — NAD+ metabolic reprogramming drives mtDNA–cGAS–STING-dependent CD8 T-cell senescence in mouse UC models with human patient correlations; senolytic clearance attenuates disease, extending senolysis rescue into a T-cell-intrinsic senescence context and IBD indication. [animal-model] (novelty: 3)
- 2026-05-07 — FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.: 2026 preclinical chondrocyte study: FMO1 elevates ROS and shifts mitochondrial dynamics toward fission to drive p16/p21-mediated chondrocyte senescence and hypertrophy, with FMO1 knockdown/inhibition or ABT-263 senolytic clearance blunting the phenotypes — adds FMO1 as an upstream metabolic enzyme node feeding cartilage senescence and extends ABT-263 senolysis to a chondrocyte context relevant to osteoarthritis. [animal-model] (novelty: 3)
- 2026-09-01 — NADMetabolic Reprogramming Drives CD8T Cells Senescence and Exacerbates Ulcerative Colitis.: 2026 preclinical UC study (mouse colitis models + human patient correlations): NAD metabolic dysregulation drives CD8 T-cell senescence via mtDNA–cGAS–STING, and senolytic clearance of these senescent CD8 T cells attenuates disease severity — extends senolytics rescue into a T-cell-intrinsic senescence context and an IBD indication. [animal-model] (novelty: 3)
- 2026-07-17 — Improving Physical Ability and Cellular Senescence Elimination in HIV: 2026 Phase II RCT protocol (NCT-listed, n=frail/prefrail adults 50+ with long-term suppressed HIV on ART): 12-week intermittent dasatinib+quercetin vs placebo with physical function and senescent-cell burden as endpoints — extends D+Q senolytic testing into a high-senescence-burden human population, but no efficacy readout yet. [human-rct] (novelty: 3)
- 2026-08-27 — Timing‐Dependent Clearance of p16‐Positive Cells Mitigates Radiation‐Induced Accelerated Aging: 2026 preclinical study: timing-dependent clearance of p16-positive senescent cells mitigates radiation-induced accelerated aging, adding a timing/window dimension to p16+ senolysis in a radiation-injury model — mouse-level mechanistic detail on an established pathway, no human readout. [animal-model] (novelty: 3)
- 2026-09-09 — 3D Culture Reverses Limbal Niche Cell Replicative Aging via FOSL1 Upregulation: 2026 in vitro study (Aging Cell): 3D culture of limbal niche cells reverses replicative senescence markers via upregulation of the AP-1 family TF FOSL1, nominating a niche-geometry → transcription factor axis as an upstream lever on the replicative-senescence program — cell-culture only, cornea-specific, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-03-25 — Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.: 2026 mouse HFD/palmitate study: high-fat diet and palmitate induce hippocampal cellular senescence with cognitive decline, largely reversed by dasatinib+quercetin senolytics — extends D+Q rescue into an obesity-driven neurodegeneration model and adds hippocampal neurons/glia to the tissue-specific senescence roster. [animal-model] (novelty: 3)
- 2026-04-15 — Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.: 2026 preclinical study: Tubeimoside I selectively kills senescent cells by binding ATP1A1 (Na+/K±ATPase α1) and disrupting K+/ion homeostasis, reducing senescence markers and improving motor function in radiation-induced and naturally aged mice — adds a mechanistically distinct (ion-pump-targeted) senolytic to the D+Q/ABT-263/PCC1 roster. [animal-model] (novelty: 3)
- 2026-05-25 — Pathological Mechanism-Inspired Biomimetic Nano-Senotherapy for Reversing Experimental Atherosclerosis in ApoEMice.: 2026 ApoE mouse study: a neutrophil-membrane-cloaked ROS-responsive nanocarrier co-delivering an MPO-inhibiting KYC dimer prodrug plus Navitoclax reversed established experimental atherosclerosis by simultaneously blocking new senescent-cell formation and clearing existing plaque senescent cells — extends dual block-and-clear senotherapy to plaque biology via biomimetic targeted delivery. [animal-model] (novelty: 3)
- 2026-05-30 — Cell senescence in chronic pain: An integrative perspective on cellular and neural mechanisms.: 2026 integrative review extends the senolytics/SASP-modulator thesis to chronic pain, proposing senescence across neurons, glia, immune, and stromal pain-processing cells as a sustaining driver of pain chronicity — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-06-03 — Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.: 2026 D-galactose mouse cognitive-aging study: dasatinib+quercetin reversed cognitive decline in parallel with downregulation of astrocytic cholesterol biosynthesis, reduced lipid accumulation, and dampened neuroinflammation — extends D+Q senolytic action to astrocytes via a cholesterol-metabolism node, with multi-omics plus genetic/pharmacologic reversal supporting causality in one model. [animal-model] (novelty: 3)
- 2026-06-12 — Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.: 2026 systematic review synthesizes the emerging paradigm of CAR T cells as ‘living senolytics’ — target discovery on senescent-cell surface antigens (uPAR, NKG2D ligands, others), engineering for the senescent niche, and preclinical fibrosis/metabolic reversal — arguing for more durable and specific clearance than small-molecule senolytics; no new primary human efficacy data. [expert-opinion] (novelty: 3)
- 2026-06-12 — Hematopoietic Rejuvenation via Natural Senolytic NSPCC1 Delays Inflammatory Aging.: 2026 preclinical study: oral NSPCC1 (bioavailability-enhanced grape-seed PCC1 senolytic formulation) extended lifespan and reduced senescence-associated inflammatory phenotypes across multiple organs in two mouse aging models, adding a reformulated natural senolytic to the D+Q/ABT-263 preclinical senolytic roster without human data. [animal-model] (novelty: 3)
- 2026-07-01 — Podocyte mPGES-2 Determines Renal Aging and Contributes to Senile Osteoporosis.: 2026 mouse study: podocyte mPGES-2 drives PGE/EP1-mediated podocyte senescence in the aging kidney; genetic deletion or SZ0232 inhibition reduces renal senescence markers and rescues α-klotho/calcitriol and bone outcomes — adds a prostaglandin-synthesis node to tissue-specific senescence with a kidney→bone systemic readout. [animal-model] (novelty: 3)
- 2026-06-27 — Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.: 2026 mouse co-exposure study: lead + hypertension drives prefrontal astrocyte senescence causing anxiety/depression-like behavior, with dasatinib+quercetin senolytics rescuing behavioral deficits — extends D+Q senolytic efficacy to a CNS astrocyte compartment in an environmental–cardiometabolic comorbidity model. [animal-model] (novelty: 3)
- 2026-07-01 — Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.: 2026 mouse AKI study: post-peak senolytic (D+Q) or verteporfin treatment clears YAP1-driven senescent tubular cells and blunts fibrotic transition, adding tubular epithelium to the tissue-specific list of senescence-driven maladaptive repair contexts responsive to timed senolysis. [animal-model] (novelty: 3)
- 2026-04-30 — Damage-induced muscle regeneration after exercise in humans: Modulatory effects of ginsenoside Rg1.: 2026 narrative review synthesizes human muscle-biopsy and exercise-adaptation data for ginsenoside Rg1, proposing a testable damage–regeneration model in which Rg1 exerts senolytic activity on injury-induced senescent muscle cells; framing-only, no new senescence measurements. [expert-opinion] (novelty: 3) [expert-opinion] (novelty: 3)
- 2026-07-01 — AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.: 2026 preclinical study of LM2556 (AI-designed LMNA 3’UTR ASO) in progeroid mice: selective depletion of progerin/farnesylated pre-lamin A rescued cardiovascular pathology and extended median lifespan ~83%, indirectly targeting the progerin-driven senescence program upstream of SASP — mouse-only, no direct senescence-clearance measurements reported here. [animal-model] (novelty: 4)
- 2026-06-17 — Resetting the epigenetic clock: cellular senescence and regenerative strategies in intervertebral disc degeneration.: 2026 intervertebral disc degeneration review frames IDD as SASP-driven and proposes senolytic clearance as the first step of a sequential clear–prime–seed regenerative roadmap for disc tissue — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-05 — A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.: MC1 melatonin–catechol hybrid preclinical study is framed around mitochondrial/ROS reprogramming and physiological-function gains rather than direct senescence readouts; touches the senescence page only via the ROS/mitochondria upstream axis already implicated in SASP, no new senescence measurements. [mechanism-plausible] (novelty: 3)
- 2026-07-01 — The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.: 2026 ocular-aging review positions RPE, trabecular meshwork, and retinal neurovascular-unit cell senescence as tissue-specific outputs of a shared aging-hallmark program, framing senolytics as a resilience lever in AMD, glaucoma, and diabetic retinopathy — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-10 — ASAP3 deficiency alleviates hepatic senescence and correlates with extended healthspan in mice.: Mouse Asap3 KO study: ASAP3 loss alleviates hepatic senescence markers with lifespan/healthspan extension, adding an actin-cytoskeleton–autophagy–mitochondria upstream node to the list of tissue-specific (liver) senescence regulators. [animal-model] (novelty: 3)
- 2026-07-11 — From local to systemic: Spinal aging in the multi-organ aging network.: 2026 spinal-aging review nominates disc, vertebral, and paraspinal-muscle cell senescence and SASP as convergent local contributors within a systemic senescence network driving degenerative spinal disease, extending the senolytics thesis to spine indications — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-15 — Resveratrol exerts anti-aging effects in young but pro-aging effects in middle-aged C. elegans via a gerosuppressive daf-16/dod-6/sod-3 axis.: 2026 companion cell-culture arm of a C. elegans resveratrol study: resveratrol was anti-senescent in normal human fibroblasts but pro-senescent in D-galactose-induced senescent fibroblasts, paralleling the worm age-dependent reversal and suggesting the compound’s effect on the senescence program flips with baseline cellular state — cell-culture only, no in vivo mammalian data. [animal-model] (novelty: 3)
- 2026-07-16 — Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation.: 2026 mouse study: Lamtor5 loss in aged macrophages triggers cGAS-driven paracrine SASP-like inflammation that propagates senescence to bystander cells; senolytic treatment alleviates downstream aging phenotypes, adding a macrophage-specific upstream trigger to the senescence program. [animal-model] (novelty: 3)
- 2026-07-17 — Manganese overload as a previously underappreciated trigger of cellular senescence: Unraveling mechanisms and therapeutic rescue by the senolytic quercetin.: 2026 C. elegans + PC12 preclinical study: manganese overload induced cellular senescence via oxidative stress, mitochondrial dysfunction, telomere attrition, and p53/p21 plus STING-related signaling, with quercetin senolysis attenuating markers — extends the environmental-metal exposure repertoire of senescence triggers, no mammalian in vivo data. [animal-model] (novelty: 3)
- 2026-07-18 — Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma.: 2026 PDAC preclinical study: gemcitabine-induced tumor-cell senescence and SASP stiffen pancreatic stroma via Piezo1 mechanotransduction, wiring a BRG1–NRF2–SLC7A11 antioxidant program that suppresses ferroptosis and drives chemoresistance; ABT-263 (senolytic) plus Erastin (ferroptosis inducer) reversed resistance in mice — extends therapy-induced senescence biology to stromal mechanics and pairs senolysis with ferroptosis induction in a cancer (not healthspan) context. [animal-model] (novelty: 3)
- 2026-07-20 — Theca cells: active orchestrators of ovarian aging.: 2026 theca-cell review adds theca cells to the list of ovarian cell types where senescence and SASP are proposed drivers of tissue dysfunction (fibrosis, steroidogenic failure), with senolytic rescue reported in preclinical models — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-01 — Ammonia Metabolism in the Aging Liver: Emerging Mechanistic Insights.: 2026 hepatic-ammonia review positions age-related ammonia accumulation as an upstream trigger of hepatocyte senescence via mitochondrial and proteostatic stress, extending the list of tissue-specific senescence inputs — narrative synthesis, no new senescence measurements. [mechanism-plausible] (novelty: 3)
- 2026-07-01 — Syringaresinol Attenuates Aging-Associated Ferroptosis-Relevant Stress Through an HIF-1α-GPX4 Defense Axis.: 2026 syringaresinol study: attenuated senescence-associated stress readouts in primary human fibroblasts in parallel with HIF-1α–GPX4-mediated ferroptosis protection, nominating ferroptosis-defense as an upstream modulator of the senescence stress program — cell-culture only, no in vivo senescence data. [mechanism-plausible] (novelty: 3)
- 2026-07-17 — Discovery of a quinoline-based senomorphic agent for the treatment of chronic kidney disease.: 2026 preclinical medicinal-chemistry study: optimized quinoline derivative C36 acts as a senomorphic — extending C. elegans lifespan and reducing SASP, senescence markers, and renal fibrosis while improving kidney function in mouse senescence and CKD models — adding a new chemical scaffold to the senomorphic toolbox with a kidney-disease indication focus. [animal-model] (novelty: 3)
- 2026-07-29 — Complosome as a key modulator of cellular senescence, aging and age-related diseases.: 2026 complosome review positions intracellular C3/C5 signaling as an upstream modulator of the senescence program via mTOR/NF-κB/AMPK crosstalk, adding intracellular complement to the growing list of proposed senescence-regulatory nodes — review-level framing, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-15 — Osteoimmune senescence in aging-related bone diseases.: 2026 osteoimmune-senescence review consolidates senescent osteoblasts, osteocytes, chondrocytes, and marrow stromal/immune cells as a shared SASP source across osteoporosis, OA, RA erosion, periodontal bone loss, and fracture non-union — conceptual synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-31 — The Physical Senotype in cellular senescence: Mechanical and physical strategies for senotherapy.: 2026 review introduces the ‘Physical Senotype’ — a shared but heterogeneous mechanical state (loss of mechanical plasticity) across senescent cells — and catalogs early-stage physical/mechanical senotherapies (substrate stiffness, mechanical stress, ultrasound) as candidate senolytic/senomorphic modalities, with specificity and safety unresolved; synthesis, no new measurements. [expert-opinion] (novelty: 3)
- 2026-07-31 — Haploidentical Hematopoietic Stem Cell Transplantation Drives Time-dependent premature T Cell Senescence: Recipient Microenvironment Modulates Donor T Cell Epigenetic Aging, Telomere Homeostasis and SASP Remodeling.: 2026 human comparative haplo-HSCT study: donor-derived CD4+/CD8+ T cells show time-dependent premature senescence (phenotypic markers, p16, γH2AX, SASP remodeling) beyond chemotherapy exposure, with recipient-age microenvironment bidirectionally modulating donor T-cell senescence — extends senescence biology to transplant-induced immune aging in humans. [human-observational] (novelty: 3)
- 2026-08-03 — Aging at the neurovascular interface: An integrative framework linking cardiovascular and cerebrovascular diseases.: 2026 neurovascular-interface review nominates senolytics as one candidate lever for disrupting shared aging biology at the heart–brain NVI, extending the senolytics thesis to cardio-cerebrovascular comorbidity — conceptual, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-07 — Cellular senescence in posterior segment neovascular diseases: A proposed feed-forward amplification model.: 2026 hypothesis-generating review proposes cellular senescence as a context-dependent feed-forward amplifier of angiogenesis, inflammation, vascular dysfunction, and fibrosis in neovascular AMD and proliferative diabetic retinopathy, framing senolytics and SASP modulators as potential adjuncts to anti-VEGF therapy — narrative synthesis of scarce human ocular data, no new measurements. [expert-opinion] (novelty: 3)
- 2026-08-05 — The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.: 2026 obesity–CVD review positions adipose-tissue senescence and SASP as a late-stage contributor to metainflammation-driven cardiovascular progression and slots senolytics into the top rung of a tiered prevention ladder after lifestyle/statins and GLP-1 agonists — review-level integration, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-10 — Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma.: 2026 ESCC preclinical study: fibrillarin (FBL) stabilizes SIRT1 and sustains nicotinamide metabolism to resist senescence in esophageal squamous cell carcinoma cells; FBL inhibition sensitizes tumor cells to senolytic therapy — nominates a nucleolar rRNA-methyltransferase as an upstream anti-senescence node and a senolytic-sensitizer target in a cancer context (not a healthspan model). [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Youthfulness of marrow Adipoqcells maintained by Cbfβ facilitates stem cell-based bone repair.: 2026 mouse study: Cbfβ loss in marrow Adipoq+ cells reduces chromatin accessibility at DNA-repair genes, triggering BMAC senescence and SASP that degrade the skeletal stem/progenitor niche and fracture repair; senolytics or AAV-Cbfβ overexpression rescue bone healing — adds a transcription-factor-controlled chromatin/DNA-repair upstream node into stromal-cell senescence and links senolytic rescue to a regenerative (bone) endpoint. [animal-model] (novelty: 3)
- 2026-08-11 — Beyond senescence entry: Individual-cell fates, population outcomes and therapeutic implications in ageing and disease.: 2026 conceptual review reframes senescence around individual-cell fate heterogeneity (arrest, death, shedding, rare escape) versus population-level persistence, arguing harmful accumulation reflects failed resolution rather than a fixed program and that therapies must distinguish beneficial from persistent senescent populations and block tumor-cell escape — synthesis, no new measurements. [expert-opinion] (novelty: 3)
- 2026-08-01 — Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.: 2026 cardiac-aging crosstalk review reframes cardiac senescence as a convergent output of adipose–heart, muscle–heart, gut–heart, and kidney–heart signaling and nominates senolytics as one nodal intervention in a multi-organ senescence network — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-17 — Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.: 2026 ovarian-aging review extends the senolytics thesis to the ovary itself, arguing that clearance of senescent granulosa/theca/stromal cells and dampening of ovarian SASP could preserve fertility window and, via reduced systemic SASP spillover, contribute to female healthspan — review-level claim, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-29 — A Purified Lycii Fructus Polysaccharide Fraction Extends Healthspan inwith an ATFS-1/UBL-5-Associated Mitochondrial Unfolded Protein Response.: 2026 Lycii Fructus polysaccharide (FSP) study: FSP reduced senescence markers in human dermal fibroblasts in parallel with ATFS-1/UBL-5-dependent UPRmt-driven C. elegans lifespan extension, nominating UPRmt activation as an upstream lever on the senescence program — cell-culture senescence readouts only. [mechanism-plausible] (novelty: 3)
- 2026-08-26 — Triple-pathway synergistic senolysis via AKAP1 silencing and calcium overload: An aptamer-functionalized DNAzyme nanoplatform for anti-pulmonary fibrosis research.: 2026 bleomycin-mouse preclinical study: an L1CAM-aptamer-functionalized DNAzyme/CaCO3 nanoplatform silences AKAP1 and induces mitochondrial calcium overload to selectively clear senescent alveolar type II cells and attenuate pulmonary fibrosis — extends targeted senolysis to a lung epithelial cell surface marker (L1CAM) and couples gene silencing with Ca²⁺ overload as a dual-trigger senolytic modality. [animal-model] (novelty: 3)
- 2026-09-01 — Solute Carrier Family 1 Member 5 (SLC1A5)-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration.: 2026 mouse partial-hepatectomy study: macrophage SLC1A5-mediated glutamine uptake prevents Kupffer-cell senescence and preserves Gas6-driven efferocytosis needed for liver regeneration; glutamine supplementation or quercetin senolysis rescues impaired regeneration — nominates an amino-acid-transport node upstream of tissue-macrophage senescence and links senolytic rescue to a regenerative (not just degenerative) endpoint. [animal-model] (novelty: 3)
- 2026-08-18 — Spatial niche remodeling of senescent liver-resident immune cells and its role in chronic liver diseases.: 2026 liver-resident immune-cell review frames Kupffer/T/NK/B-cell senescence (p53/p21, p16/Rb) as spatially organized along the portal–central axis and driving steatosis→fibrosis→HCC progression, motivating subset-specific senotherapeutics — conceptual synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-09-06 — Mitochondria-endoplasmic reticulum contact sites (MERCS/MAM): Multi-layered upstream regulators of microglial senescence in Alzheimer’s disease.: 2026 MERCS/MAM–AD review proposes microglial senescence as a downstream consequence of contact-site dysfunction (Ca²⁺ overload, lipid dysregulation, ER stress), extending the senescence framework to a CNS-resident myeloid cell type via a mitochondria–ER interface — conceptual, no new senescence measurements in microglia. [mechanism-plausible] (novelty: 3)
- 2026-09-08 — LAPTM5 correlates with RPE senescence and subretinal fibrosis through the LAPTM5-WWP2-OPTN mitophagy cascade and cGAS/STING activation in a D-galactose-induced aging model.: 2026 D-gal RPE aging study: LAPTM5-driven WWP2 degradation impairs OPTN-mediated mitophagy and activates cGAS–STING to drive RPE senescence and subretinal fibrosis; RPE AAV-LAPTM5 knockdown or STING inhibitor rescues fibrotic lesions — adds a mitophagy-to-DNA-sensing route into tissue-specific senescence in a retinal aging model. [animal-model] (novelty: 3)
- 2026-06-19 — Centenarian SIRT6 variants elevate SIRT6 protein and enhance cellular senescence resistance.: 2026 SIRT6 centenarian-variant study: knock-in of Ashkenazi centenarian SIRT6 missense variants in hESC-derived lineages enhances cellular senescence and progerin-stress resistance, with AAV-SIRT6 or fucoidan-FV partially phenocopying the effect in progeria fibroblasts — links human longevity genetics to an intrinsic senescence-resistance program upstream of SASP. [mechanism-plausible] (novelty: 4)
- 2026-06-17 — Synergistic nanosenolytic therapy reverses age-related dry eye disease by targeting cellular senescence and oxidative stress.: 2026 preclinical eye drop study: a pH-responsive polypeptide nanocarrier co-delivering quercetin and SOD improved corneal penetration, suppressed SASP and oxidative stress, and reversed age-related dry eye disease in aged models — extends senolytic + antioxidant combination delivery to a local ocular surface application. [animal-model] (novelty: 3)
- 2026-07-01 — A critical role for mitochondrial dynamics in cigarette smoke condensate-induced RPE senescence.: 2026 preclinical RPE study (cultured RPE + chronic cigarette smoke-exposed mice): cigarette smoke condensate induces retinal pigment epithelium senescence via impaired DRP1-dependent mitochondrial fission, defective mitophagy, elevated mitochondrial ROS, and mTOR activation — extends senescence triggers to an environmental toxicant relevant to AMD. [animal-model] (novelty: 3)
- 2026-07-01 — Multi-omics profiling reveals systemic rejuvenation of the aged kidney through senolytic therapy.: 2026 multi-omics (proteomic + single-cell) mouse study: long-term dasatinib+quercetin cleared senescent cells in naturally aged kidneys and normalized aging/inflammatory intercellular communication signatures across renal cell types, extending D+Q’s canonical senolytic effect into a systems-level renal rejuvenation readout. [animal-model] (novelty: 3)
- 2026-07-01 — A Non-Canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver.: 2025/2026 mouse hepatocyte MLKL overexpression study: MLKL drives hepatocyte senescence and paracrine SASP-like signaling in the aging liver via a non-necroptotic route, nominating a necroptosis-pathway component as an upstream trigger of tissue-specific senescence. [animal-model] (novelty: 3)
- 2026-06-24 — Mitochondrial transcription factor A: linking mtDNA maintenance, mitochondrial stress responses, and inflammaging.: 2026 TFAM review implicates loss of TFAM homeostasis (via nucleoid instability and mtDNA release) as an upstream driver of the senescence program, adding a mtDNA-maintenance node to the growing list of mitochondrial triggers of SASP — conceptual synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-09 — Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.: 2025 mitochondrial-ubiquitination review implicates the WAC–PINK1–Parkin axis and ROS–E3 ligase feedback loops in MSC senescence, framing failed mitochondrial ubiquitination calibration as an upstream trigger of stem-cell senescence programs — narrative synthesis of prior preclinical work. [expert-opinion] (novelty: 3)
- 2026-07-13 — HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.: 2026 preclinical OA study: HMGCR-driven cholesterol biosynthesis, activated via an AKT1–Insig1–SCAP axis, accelerates fibroblast-like synoviocyte senescence in osteoarthritic joints; targeted HMGCR inhibition reverses FLS senescence, synovitis, cartilage loss, and pain in OA mice — nominates cholesterol biosynthesis as an upstream metabolic input to tissue-specific senescence and hints at statin-adjacent repurposing, still preclinical. [animal-model] (novelty: 3)
- 2026-07-13 — Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice.: 2026 HFD-obese mouse study: uPAR-targeted nanoparticles co-delivering dasatinib+quercetin selectively cleared senescent adipocytes and improved insulin sensitivity — a targeted-delivery refinement of the canonical D+Q senolytic combo that positions uPAR as an adipose-senescence surface marker for cell-selective clearance, still preclinical. [animal-model] (novelty: 3)
- 2026-06-29 — Mechanistic redundancy and hierarchy of aging mechanisms: implications for strategies to extend healthspan and biomarker integration.: 2026 hierarchy review reclassifies cellular senescence as a secondary/tertiary downstream hallmark responding to primary insults (genomic/mtDNA damage, telomere attrition, sex-hormone decline), predicting senolytics alone will underperform relative to upstream multi-target prevention — conceptual reframing, no new senescence data. [expert-opinion] (novelty: 3)
- 2026-07-03 — Chlorella Hot Water Extract Restores Collagen Production in Senescent Fibroblasts Through Reversal of miR-193a-5p-Mediated Translational Repression of COL1A1.: 2026 in vitro fibroblast study: chlorella hot water extract reverses collagen loss in senescent human fibroblasts by normalizing miR-193a-5p–mediated translational repression of COL1A1, nominating a miRNA-translation axis as a druggable node within the senescent secretory/ECM phenotype — cell-culture only, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-07-15 — The SIRT5-SUCLG2 desuccinylation axis delays ovarian aging via a mitochondrial-epigenetic regulatory mechanism.: 2026 ovarian aging study implicates a SIRT5–SUCLG2 desuccinylation failure in age-related ovarian decline via acetyl-CoA–driven H4K8ac; framed as reproductive aging rather than classical senescence, but links mito-epigenetic crosstalk to the broader tissue-aging program targeted by senescence biology. [animal-model] (novelty: 3)
- 2026-07-16 — Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated Cardioprotection.: 2026 narrative review reframes GLP-1RA cardioprotection as partly mediated by attenuation of vascular-cell senescence and SASP in cardiometabolic disease, linking an approved drug class to senescence biology without new primary senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-17 — Palmitoylation in cardiovascular aging and disease: Mechanistic insights and therapeutic opportunities.: 2026 palmitoylation-in-CV-aging review implicates dysregulated protein palmitoylation as a contributor to cardiovascular cell senescence within a proposed metabolic vicious cycle coupling mitochondrial dysfunction and oxidative stress to SASP-adjacent phenotypes — conceptual synthesis, no new senescence measurements. [mechanism-plausible] (novelty: 3)
- 2026-07-19 — Rethinking frailty as a disorder of mitochondrial adaptability, from energetic congestion to systemic vulnerability.: 2026 frailty perspective positions senescent-cell accumulation as a manifestation of energetic-congestion-driven loss of mitochondrial adaptability in aged muscle and adipose, integrating sarcopenic-obesity multi-omics with senescence biology — conceptual synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-07-23 — Exercise attenuates atherosclerosis by inhibiting eWAT aging via targeting SIRT1/pyruvate carboxylase pathway.: 2026 HFD mouse study: voluntary exercise attenuates atherosclerotic plaque burden by suppressing epididymal white adipose tissue senescence; senolytic clearance partially phenocopies the protective effect, positioning eWAT as a peripheral senescent-cell reservoir upstream of vascular aging. [animal-model] (novelty: 3)
- 2026-07-14 — TRF2 enriched cytoplasmic chromatin drives cGAS-STAT1-mediated inflammation in senescence.: 2026 preclinical study: senescent cells accumulate TRF2-marked cytoplasmic chromatin fragments that engage cGAS–STAT1 to sustain SASP and reinforce the senescent state; metformin and JAK–STAT inhibitors dampen this feedforward loop in models. [animal-model] (novelty: 3)
- 2026-07-01 — Lysine methyltransferase methyltransferase-like 13 regulates bone marrow mesenchymal stem cells osteo-adipogenic differentiation and senescence in osteoporosis via the Foxa1/HES-1 axis.: 2026 preclinical BMSC/ovariectomy study: METTL13 promotes BMSC senescence and adipogenic bias via the Foxa1/HES-1 axis, adding a lysine methyltransferase to the growing list of methyltransferase-mediated senescence regulators (alongside PRMT6/FOXG1) and linking stromal senescence to osteoporosis-relevant lineage skewing. [animal-model] (novelty: 3)
- 2026-08-01 — Loss of BCAP31 or POLR1E Accelerates Aging in C. elegans and is Linked to Senescence in Vascular Endothelium.: 2026 C. elegans + human endothelial cell study: loss of CD44 interactome partners BCAP31 or POLR1E drives premature endothelial senescence and shortens nematode lifespan, extending the CD44 receptor’s role beyond ECM/hyaluronan signaling into an intracellular anti-senescence axis. [animal-model] (novelty: 3)
- 2026-08-10 — Alterations of actin in aging.: 2026 actin-aging review positions cytoskeletal disorganization as an upstream contributor to the senescence program (e.g., via mechanotransduction and cytoskeleton-linked stress signaling), extending senescence triggers beyond DDR/telomere/SASP-centric models — narrative synthesis, no new senescence measurements. [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Dioscin extends lifespan and ameliorates aging associated phenotypes in association with the endoplasmic reticulum unfolded protein response.: 2026 preclinical dioscin study: p16/p21 senescence markers reduced in aged mice alongside C. elegans lifespan extension, with the effect mechanistically pinned to ER-UPR (XBP-1/PERK/IRE1α/ATF6) activation rather than direct senolysis — nominates proteostasis restoration as an upstream lever on the senescence program. [animal-model] (novelty: 3)
- 2026-08-10 — Preserving joint healthspan in knee osteoarthritis: a geroscience-guided review of non-surgical therapies and genicular artery embolization.: 2026 geroscience-framed review reframes knee osteoarthritis as a joint-aging phenotype in which chondrocyte senescence/SASP is invoked as one substrate; positions weight loss and exercise as core interventions while noting disease-modifying senolytic/senomorphic therapies for KOA remain unvalidated in humans — narrative synthesis, no new senescence measurements. [expert-opinion] (novelty: 3)
- 2026-08-07 — Stress management by benzodiazepines in septic shock and critical illness: mechanistic and clinical evidence supporting alternative sedative strategies.: 2026 review proposes benzodiazepines in septic shock/ICU accelerate an ‘iatrogenic aging’ phenotype by pushing stressed cells toward senescence when autophagic clearance is antagonized, linking sedation choice to post-ICU/post-sepsis senescent-cell burden — conceptual synthesis of preclinical and clinical literature, no direct senescence readout in patients. [mechanism-plausible] (novelty: 3)
- 2026-04-01 — Dilating the aging clock with light.: 2026 review argues light-based modalities (UV/visible exposure, PDT-generated ROS, optogenetic organelle stressors) can induce senescence phenotypes on demand in defined cell populations, positioning them as tunable senescence-induction tools rather than confounded chronic stressors — review-level claim, no new data. [expert-opinion] (novelty: 3)
- 2026-08-12 — PRMT6 drives hearing loss by promoting asymmetric arginine dimethylation-mediated FOXG1 degradation and suppressing mitophagy.: 2026 D-gal cochlear aging model: PRMT6-mediated FOXG1 degradation suppresses mitophagy and induces senescence phenotypes in hair cells and HEI-OC1 cells, reversed by PRMT6 inhibition — links arginine methyltransferase activity to tissue-specific senescence via mitochondrial quality control. [animal-model] (novelty: 3)
- 2026-07-30 — Reversible Mechano-Regulation of Cellular Senescence: Effects of Substrate Stiffness on Cells.: 2026 in vitro study: culturing cells on softer hydrogel substrates reversed senescence markers and upregulated longevity-associated gene expression, nominating substrate stiffness/mechanotransduction as a modifiable input to the senescence program — cell-culture only, no in vivo or human data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — An ANGPTL8-AKT2-mTOR Axis Drives Adipose Senescence and Aging-Related Functional Decline.: 2026 mouse + human cohort study identifies ANGPTL8 as an endocrine driver of adipose senescence via AKT2–mTOR–S6K signaling; Angptl8 deletion extends mouse lifespan and circulating ANGPTL8 tracks with human biological age and mortality — nominates a fat-tissue-secreted trigger upstream of the senescence program. [animal-model] (novelty: 4)
- 2026-08-17 — Microglia activation by derepression of endogenous retroviruses drives inflammation and cellular senescence.: 2026 mouse study links DAXX-loss-driven RTE derepression in microglia to a PML/interferon-dependent senescent replacement state, extending SASP biology to a CNS-resident myeloid cell type via heterochromatin decompaction rather than classical DDR triggers. [animal-model] (novelty: 3)
- 2026-08-01 — The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.: 2026 cell-based mechanistic study: melatonin acts through the vitamin D receptor to downregulate p16Ink4a and upregulate OCT4, coupling anti-senescence signaling to a stemness/osteogenic-differentiation axis in cultured cells — pathway detail on an established compound, no in vivo or human outcome data. [mechanism-plausible] (novelty: 3)
- 2026-09-01 — hTERT Immortalization Stabilizes Human Umbilical Cord MSCs and Maintains Their Small Extracellular Vesicles With Preserved Immunomodulatory Activity and Primordial Follicle-Activating Capacity.: 2026 preclinical study: hTERT overexpression in late-passage human umbilical cord MSCs attenuates replicative senescence markers and preserves the immunomodulatory/regenerative activity of their small extracellular vesicles, dissociating donor-cell senescence from sEV functional decline via a miR-217-5p/SIRT1 cargo axis. [mechanism-plausible] (novelty: 3)
- 2026-08-22 — Exercise and p21 signaling in central nervous system aging and senescence: A context- and dose-dependent relationship.: 2026 integrative preclinical review proposes a context/dose-dependent, three-state model of exercise–CNS p21 signaling (physiological attenuation, transient adaptive induction, maladaptive sustained p53–p21 injury under overload), framing exercise as senomorphic/stress-preventive rather than a proven CNS senolytic — synthesis of prior model data, no new measurements. [mechanism-plausible] (novelty: 3)
- 2026-08-24 — Loss of Erbin in tubular epithelial cells sensitizes mice to acute kidney injury and aggravates renal fibrosis.: 2026 mouse study with human CKD expression correlation: conditional loss of the RAS-adapter protein Erbin in kidney tubular epithelial cells drives G2/M cell-cycle arrest and senescence, worsening AKI and renal fibrosis, while Erbin restoration is protective — nominates tubular Erbin as an upstream node gating senescence in aging-associated nephropathy. [animal-model] (novelty: 3)
- 2026-08-25 — LMNA R527C pathogenic variant causes an inflammation-driven segmental progeroid syndrome via triggering DNA-sensing pathways.: 2026 LMNA R527C progeroid study (patient MSCs + mice): cGAS–STING hyperactivation downstream of disrupted Lamin A–DNA-binding-protein interactions drives senescence, and blocking DNA sensing rescues the senescent phenotype — links nuclear envelope dysfunction to senescence via cytosolic DNA sensing. [animal-model] (novelty: 3)
- 2026-08-26 — The Reductive Stress Nexus: Integrated Pathways of Metabolic Dysregulation, Senescence and Blood-Brain Barrier Failure in Neurodegenerative Disease and Brain Aging.: 2026 review positions cerebrovascular and neural cell senescence as a downstream node of reductive-stress-driven redox imbalance feeding SASP and BBB failure in neurodegeneration; conceptual linkage, no new measurements. [mechanism-plausible] (novelty: 3)
- 2026-08-17 — Epigenetic Skeletal Muscle Memory: The Impact of Physical Activity on Aging and Post-Injury Regeneration.: Review implicates satellite-cell senescence and SASP as contributors to the age-related erosion of muscle regenerative memory; asserted mechanistically, not tested in this paper. [mechanism-plausible] (novelty: 3)
- 2026-08-11 — Senolytic Treatment Triggered by Carotid Occlusion Confers Protection Against Later Acute Ischemic Stroke in Aged Rats.: 2026 preclinical rat study: chronic dasatinib+quercetin after unilateral carotid occlusion reduced cerebrovascular senescence markers, infarct size, and spreading-depolarization frequency in aged rats subsequently subjected to acute ischemic stroke — senolytic pre-treatment as stroke-resilience mechanism in a comorbid aging model. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Corrigendum to "Qi-Gu capsule alleviates osteoporosis by inhibiting mesenchymal stem cell senescence via the HIF-1α/AMPK axis" [Phytomedicine 142 (2025) 156764].
15-nov-2026
novelty 1
per-area 1
mentions
Artificial intelligence-assisted discovery of natural product geroprotectors: target prediction, aging biomarker identification, and drug repurposing.
13-nov-2026
novelty 2
per-area 2
mentions
Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.
13-nov-2026
novelty 3
per-area 3
strengthens
Cellular senescence and the hallmarks of ageing: Evaluating evidence for a causal mechanistic role.
13-nov-2026
novelty 3
per-area 3
strengthens
Interfering in the USP25-SIRT1 Interaction Reduces the Onset of Cellular Senescence
13-nov-2026
novelty 3
per-area 3
strengthens
Aging Remodels the Female Skeletal Muscle Proteome Toward Matrix, Chromatin and Lysosomal Programs that Track Loss of Physical Function
12-nov-2026
novelty 3
per-area 3
strengthens
Vascular Senescence and Atherosclerotic Plaque Vulnerability
12-nov-2026
novelty 2
per-area 2
strengthens
Sanmiao San Attenuates D-galactose-induced Chondrocyte Senescence by Regulating the FoxM1-p21 Signaling Pathway.
12-nov-2026
novelty 2
per-area 2
strengthens
The DNA Damage Response Induces PD-L1 Expression and Immune Evasion in Senescent Cells
12-nov-2026
novelty 3
per-area 3
strengthens
Transcriptomic Characterization of Cellular Senescence in Human Donor Livers Before Transplantation
12-nov-2026
novelty 3
per-area 3
strengthens
MLL, TERRA, and telomere chromatin dynamics in replicative senescence and aging.
11-nov-2026
novelty 3
per-area 3
strengthens
A genetically encoded system to purify senescent cells.
11-nov-2026
novelty 3
per-area 3
strengthens
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026
novelty 2
per-area 2
strengthens
The neuro-inflammaging triangle: a self-amplifying circuit of protein pathology, senescence-associated secretory phenotype and innate immunity in neurodegenerative disease.
10-nov-2026
novelty 3
per-area 3
strengthens
A Supplement Kills Senescent Cells and Extends Life in Mice
10-nov-2026
novelty 4
per-area 4
strengthens
Cepharanthine Identified as a Novel Senolytic
10-nov-2026
novelty 3
per-area 2
mentions
Senescence‐Associated Loss of α‐Synuclein in Brain Microvascular Endothelium Compromises Tight Junctions and Disrupts Blood–Brain Barrier Integrity
09-nov-2026
novelty 3
per-area 3
strengthens
TMAO regulates renal tubular epithelial cell senescence through circVmn2r1.
09-nov-2026
novelty 3
per-area 3
strengthens
The lncRNA SEPT5-GP1BB-encoded peptide ARP, upregulated by 17β-estradiol, retards HO-induced senescence of human umbilical vein endothelial cells by promoting autophagy.
09-nov-2026
novelty 3
per-area 3
strengthens
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
09-nov-2026
novelty 3
per-area 3
strengthens
CASM regulates lysosomal expansion and cell fate during senescence.
09-nov-2026
novelty 3
per-area 3
strengthens
Resistant hypertension and accelerated vascular aging: evidence for PTEN-AKT-associated cellular senescence.
05-nov-2026
novelty 3
per-area 3
strengthens
Senescent CD8 T effector memory cells are functionally impaired, enriched in aging and disease, and a barrier to immunotherapy.
03-nov-2026
novelty 3
per-area 3
strengthens
Evidence for spermine oxidase (SMOX) as a regulator of skeletal muscle mass throughout the lifespan.
03-nov-2026
novelty 3
per-area 3
strengthens
Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis.
02-nov-2026
novelty 4
per-area 4
strengthens
The AIM2 inflammasome drives age-dependent cardiac dysfunction following ischemia-reperfusion in mice.
01-nov-2026
novelty 3
per-area 3
strengthens
Enabling Photoacoustic Imaging and Photothermal Elimination of Senescent Cells via an Activatable Theranostic Probe.
01-nov-2026
novelty 3
per-area 2
strengthens
Inflammaging as a Dynamic Process in Ageing: Context, Regulation and Functional Consequences.
01-nov-2026
novelty 3
per-area 3
strengthens
Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions.
01-nov-2026
novelty 4
per-area 4
strengthens
Multi-Omics Reveals STAT1 as a Central Regulator of Oxidative Stress-Induced Senescence in the Aging Retina.
01-nov-2026
novelty 3
per-area 3
strengthens
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
29-oct-2026
novelty 3
per-area 2
strengthens
Identification of an Endothelial Senotype Predicted by Ion Channel Expression in Aged Murine Perigonadal Adipose Tissue.
28-oct-2026
novelty 3
per-area 3
strengthens
Leptin Neutralization Attenuates Inflammaging in Endothelial and Immune Cell Models.
23-oct-2026
novelty 3
per-area 3
strengthens
Mechanisms of the interaction between aging of the male reproductive system and obesity, and clinical management strategies (Review).
23-oct-2026
novelty 2
per-area 2
mentions
Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.
23-oct-2026
novelty 3
per-area 3
strengthens
Proteostasis stress alters mitochondrial levels and localization of SOD2 during cellular senescence.
20-oct-2026
novelty 3
per-area 3
strengthens
Correction to "AMPK-upregulated microRNA-708 Plays as a Suppressor of Cellular Senescence and Aging via Downregulating Disabled-2 and mTORC1 Activation".
13-oct-2026
novelty 1
per-area 1
mentions
Sympathetic Regulation of Bone Metabolism: Mechanisms across Homeostasis, Aging and Disease.
11-oct-2026
novelty 2
per-area 2
mentions
THE AGING PURINOME: A PURINERGIC FRAMEWORK LINKING THE HALLMARKS OF AGING TO INFLAMMAGING.
10-oct-2026
novelty 3
per-area 3
strengthens
Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
09-oct-2026
novelty 3
per-area 3
strengthens
Organoids for modeling cellular senescence and age-related pathology: From experimental reconstruction to mechanistic and translational applications.
08-oct-2026
novelty 2
per-area 3
strengthens
Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.
08-oct-2026
novelty 3
per-area 3
strengthens
Phosphodiesterase 4 inhibitors extend lifespan of C. elegans and attenuate cellular senescence of mouse embryonic fibroblasts.
08-oct-2026
novelty 3
per-area 3
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 3
strengthens
Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.
07-oct-2026
novelty 3
per-area 2
strengthens
Treatment benefit does not establish senolysis or lifespan extension.
06-oct-2026
novelty 2
per-area 2
weakens
Declining Autophagy Impairs Senescent Cell Clearance
06-oct-2026
novelty 3
per-area 3
strengthens
Chronic Inflammation in the Aging of Bone and Brain Tissue
06-oct-2026
novelty 2
per-area 2
strengthens
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics
06-oct-2026
novelty 2
per-area 2
strengthens
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026
novelty 3
per-area 3
strengthens